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Abstract 
Background: Gastroenteritis is an important cause of morbidity in older adults, 
resulting in a significant health burden globally. The aims of this thesis were to 
describe the epidemiology of gastroenteritis in older adults, and to investigate 
factors associated with hospitalisation with all-cause and cause-specific 
gastroenteritis in a cohort of middle-aged and older Australians. 
Methods: I used design-based logistic regression and proportional hazards 
regression to analyse two datasets: (1) a national survey of gastroenteritis in the 
Australian community conducted in 2008–2009; and (2) a large-scale population-
based cohort of middle-aged and older Australians with data linkage to 
hospitalisations, pharmaceuticals, notifiable diseases and deaths data. 
Additionally, I conducted a systematic review and meta-analysis of Clostridium 
difficile infection among people with inflammatory bowel disease.  
Results: I estimated that 78,356 people aged ≥65 years old visited a doctor due 
to gastroenteritis in Australia annually, with 157,317 million courses of 
medication use in one year period from 2008−2009. From population-based 
cohort data, I demonstrated that the incidence of hospitalisation with 
gastroenteritis increased with older age; from 2.4 per 1,000 person-years in 
adults aged 45-54 years old to 9.5 per 1,000 in those aged ≥65 years. Compared 
to adults aged 45-54 years old, older persons had a higher incidence of 
hospitalisation with Salmonella infection and C. difficile infection. After 
adjustment, the risk of hospitalisation with gastroenteritis differed
vii 
 depending on sex and region of residence. Poor self-rated health and use of 
proton pump inhibitors (PPI) were significantly associated with gastroenteritis 
hospitalisation. Hospitalisation with C. difficile infection was associated with 
longer hospital stays, greater in-hospital costs and higher in-hospital deaths 
compared to hospitalisation without C. difficile infection. In a meta-analysis of 
six international studies included in the systematic review, C. difficile infection 
was a significant risk factor for colectomy among patients with inflammatory 
bowel disease (Odds Ratio: 1.90; 95%CI 1.23-2.93). 
Conclusions:  This thesis demonstrates a significant burden of gastroenteritis 
in older Australians. Incidence of hospitalisation with all-cause and cause-
specific gastroenteritis increases significantly with age. Future efforts should 
focus on defining and improving preventive measures for gastroenteritis 
hospitalisation among the elderly. The risk of hospitalisation varies by sex and 
region of residence, which reflects differences in exposure. PPI use is 
significantly associated with gastroenteritis hospitalisation. Given the 
widespread of PPI use, particularly among older people, clinicians should be 
aware of this potential association when considering PPI therapy. In addition, 
early recognition and supportive treatment of diarrhoea in older patients with 
poor self-rated health may prevent subsequent hospitalisation and improve 
their health outcomes. 
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SUMMARY
The aim of this study was to estimate the healthcare usage and loss of productivity due to
gastroenteritis in Australia using the National Gastroenteritis Survey II. In 2008–2009, 7578
participants across Australia were surveyed about infectious gastroenteritis by telephone
interview. A gastroenteritis case was deﬁned as a person experiencing 53 loose stools and/or
52 vomits in a 24-h period, excluding cases with a non-infectious cause for their symptoms, such
as pregnancy or consumption of alcohol. Lost productivity was considered any lost time from
full- or part-time paid work due to having gastroenteritis or caring for someone with the illness.
Interference with other daily activities was also examined along with predictors of healthcare-
seeking practices using multivariable regression. Results were weighted to obtain nationally
representative estimates using Stata v. 13·1. Of the 341 cases, 52 visited a doctor due to
gastroenteritis, 126 reported taking at least one medication for their symptoms and 79 cases
reported missing 51 days’ paid work due to gastroenteritis. Gastroenteritis results in a total of
13·1 million (95% conﬁdence interval 6·7–19·5) days of missed paid work each year in Australia.
The indirect costs of gastroenteritis are signiﬁcant, particularly from lost productivity.
Key words: Australia, healthcare utilization, infectious gastroenteritis, lost productivity.
INTRODUCTION
Gastroenteritis is a common illness, resulting in an esti-
mated 15·9 million cases in Australia in 2010 [1]. While
not all cases of gastroenteritis will present to a doctor or
hospital due to themild nature of symptoms for thema-
jority of episodes, gastroenteritis-associated healthcare
utilization and lost productivity can result in consider-
able costs to society [2, 3].
Gastroenteritis often interferes with daily activities,
such as working, school attendance, and recreational
activities. In particular, examining how much time is
taken off from paid work to recover from gastroenter-
itis or care for someone else who is ill highlights the
effect of gastroenteritis on lost productivity. This
productivity loss can be very expensive and has been
identiﬁed as the largest contributor to total costs for
all gastroenteritis [3–6]. Lost productivity attributable
to gastroenteritis can have a substantial burden on
society due to its commonness.
In 2001, a nationally representative cross-sectional
survey, the National Gastroenteritis Survey I (NGSI
2001), was undertaken to determine the population
burden of infectious gastroenteritis in Australia [7].
The NGSI found that about 20% of people with
gastroenteritis attended a medical practitioner and,
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of these, 20% submitted faecal specimens for testing [8].
In addition, gastroenteritis resulted in around 0·9 mil-
lion prescriptions for antibiotics [8]. Robust estimates
of healthcare-seeking behaviour can improve the
understanding of the number of cases reported to public
health surveillance systems and highlight the impact of
gastroenteritis on the healthcare system.
In2008–2009,weconductedtheNationalGastroenteritis
SurveyII (NGSII2008) – aretrospectivecross-sectional
survey to identify the population burden of infectious
gastroenteritis in Australia in that year. The method-
ology applied in NGSII was a repeat of NGSI to assess
changes in the prevalence of gastroenteritis inAustralia.
In this paper we analyse healthcare system utilization,
medicationusage, and lostproductivity for cases report-
ing gastroenteritis during NGSII.
METHODS
TheNGSIIwas a retrospective cross-sectional computer-
assisted telephone survey across all States and Territories
of Australia during a 1-year period fromFebruary 2008
to January 2009 with a sample of 7578 individuals. The
full methods for NGSII are described elsewhere [9].
Information on demographic characteristics, gastro-
intestinal and respiratory symptoms, duration of illness,
illness risk factors, healthcare-seeking behaviour, medi-
cation usage, and interference of illness with daily life
were included in the survey questionnaire. This paper
is concerned with the data collected from cases on ques-
tions of healthcare-seeking behaviour, medication
usage, and lost productivity due to gastroenteritis.
Case deﬁnition
The case deﬁnition for gastroenteritis used in our
study was a respondent experiencing 53 episodes of
diarrhoea and/or 52 episodes of vomiting in a 24-h
period over the previous 4 weeks, excluding cases
who identiﬁed a non-infectious cause for their symp-
toms, such as pregnancy or consumption of alcohol.
As respiratory infections can result in gastrointestinal
symptoms, an adjustment was made by applying a
stricter deﬁnition if the person had concomitant re-
spiratory symptoms, requiring 54 loose stools and/
or 53 vomits in a 24-h period [10]. The number and
duration of gastrointestinal symptoms were evaluated.
Duration was calculated from the ﬁrst to the last day
of experiencing either diarrhoea or vomiting. Lost
productivity was deﬁned as any time lost from full-
or part-time paid work due to having gastroenteritis,
or caring for someone with the illness.
Analysis
To provide nationally representative results, post-
stratiﬁcation was applied to all analyses to adjust for
known differences between the survey sample and the
Australian population byweighting to the 2008 resident
population age, sex and State from the Australian
Bureau of Statistics. All estimates were based on the
Australian population in 2008 (21·4 million persons).
The method is described in detail elsewhere [9].
We calculated weighted proportions and estimated
the number of cases nationally that sought health ad-
vice, took medications or submitted a stool for cul-
ture. Time lost from work and daily activities due to
infectious gastroenteritis were examined in relation
to demographic characteristics of survey respondents
and the severity of their illness. Daily activities was
deﬁned as ‘working, attending school, or recreational
activities’.
To examine whether symptoms and duration of ill-
ness were associatedwith the likelihood of cases visiting
a doctor, design-based logistic regression was used to
calculate crude odds ratios of explanatory variables of
all individual symptoms, duration of illness, age
group, sex, income, and Indigenous status [11]. Those
explanatory variables that were statistically signiﬁcant
were then entered into a backwards stepwise multivari-
able logistic regression process and those that signiﬁ-
cantly improved the ﬁt of the model formed the ﬁnal
model. Statistical signiﬁcance was taken at P < 0·05.
The Hosmer–Lemeshow test was used to check model
ﬁt [12].
Survival analysis was used to estimate the mean
duration of illness to account for respondents with on-
going illness at the time of interview. Analyses were
undertaken with Stata statistical package, version
13·1. The ‘svyset’ commands in Stata was used to ac-
count for survey design and post-stratiﬁcation to the
Australian population [13].
Ethical considerations
Verbal consent was obtained from all participants and
from parents and guardians on behalf of children dur-
ing the interview. Where the respondent was a child
aged <15 years, questions were answered by their
carer. Adolescents aged 15–17 years answered ques-
tions themselves following consent from their parents
or guardians. The study and consent procedures were
approved by the ethics committees of the Australian
Government Department of Health, the Australian
National University and the NSW Cancer Council.
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RESULTS
Of 7578 respondents in the NGSII survey, 555 respon-
dents reported experiencing diarrhoea or vomiting
in the 4 weeks prior to interview, with 341 meeting
the case deﬁnition for infectious gastroenteritis.
Reporting of recent gastroenteritis episodes was high-
est in children aged <5 years (Table 1).
Health-seeking behaviour
Overall, 123 cases presented their illness to a health
professional, of which doctors and pharmacists were
the health professionals most frequently seen. There
were 52 cases visiting a doctor, of these, 11 cases sub-
mitted a stool sample for testing. When weighted to
the Australian population by age, sex, and State,
there were an estimated 2·7 million [95% conﬁdence
interval (CI) 1·8–3·6] people visiting health profession-
al due to gastroenteritis in Australia annually, with
517 219 (95% CI 119816–914621) stool tests submitted
in one year (2008–2009).
Factors associated with cases visiting a doctor
In univariate analysis, age, sex, household income,
Indigenous status, diarrhoea, blood in stool, nausea,
loss of appetite, aches, headache, stiff neck and vomit-
ing were not found to be statistically signiﬁcantly asso-
ciated with visiting a doctor. Earache, stomach cramps,
respiratory symptoms, fever, and the duration of
illness were signiﬁcantly associated with cases visiting
a doctor for gastroenteritis, and were therefore entered
into the backward stepwise regression building. In the
ﬁnal model, having stomach cramps, fever, respiratory
symptoms, and duration of illness were signiﬁcantly
associated with cases visiting a doctor (Table 2).
Cases with stomach crampswere less likely to seekmed-
ical consultation [adjusted and weighted odds ratio
(aOR) 0·3, P = 0·001], while cases with fever were
more likely to visit a doctor for their illness (aOR 2·5,
P = 0·01). Cases symptomatic for 3 or 4 days were
more likely to see a doctor compared to those who
were ill for 1 or 2 days (aOR4·2, P < 0·001, as were
those ill for55 days (aOR 6·1, P < 0·001).
Overall, 12 of the cases that visited a doctor were
asked to submit a stool specimen. Of those who were
asked, 11 out of 12 cases submitted a specimen.
Duration of55 days was associated with higher likeli-
hoodof a case submitting a specimen (OR4·6,P= 0·08).
The Hosmer-Lemeshow goodness-of-ﬁt test showed
a good ﬁt for the ﬁnal logistic model (P = 0·8)
Medications for gastroenteritis
Of the 341 cases, 126 (weighted 32·2%) reported tak-
ing at least one medication to treat or relieve symp-
toms and of these, 19 (21·0%) received a prescription
from a doctor, 28 (18·6%) chose medication based
on a chemist’s advice, 41 (29·3%) chose medication
without professional advice, and 19 (9·2%) used left-
over medication or received it from a friend. Half of
cases reporting medication usage for gastroenteritis
reported taking only one medication, while 16 cases
reported taking at least three types of medication.
Overall, 64 (15·5%) cases took antidiarrhoeal medi-
cation for their conditions. Sixty respondents reported
the generic or brand name of the antidiarrhoeal medi-
cation, among which the main type reported was lo-
peramide. Additionally, 68 (15·6%) respondents with
gastroenteritis used a painkiller for their conditions,
and the main types reported were paracetamol and
non-steroidal anti-inﬂammatory drugs (NSAIDS).
Of all cases, eight (1·8%) reported antibiotic usage
and ﬁve of those provided the speciﬁc brand name, in-
cluding four courses of penicillin usage and one course
of augmentin.
Extrapolating data to the Australian population,
there were an estimated 5·5 million (95% CI 4·4–6·6)
courses of medication usage for gastroenteritis each
year, including 2·1 million (95% CI 1·4–2·8) courses
of antidiarrhoeals (Table 3).
Table 1. Age and sex distribution of survey respondents

















0–4 249 (6·4) 42 (6·3) 12·1
5–9 249 (6·3) 16 (4·4) 6·4
10–19 497 (13·4) 20 (12·8) 5·6
20–29 507 (14·1) 47 (15·6) 9·1
30–39 802 (14·3) 53 (15·4) 6·1
40–49 1064 (14·3) 54 (16·0) 6·1
50–59 1374 (12·6) 52 (12·4) 3·5
60–64 755 (5·3) 25 (4·3) 2·7
565 2081 (13·3) 32 (12·9) 1·2
Sex
Male 3024 (49·7) 142 (47·6) 6·2
Female 4554 (50·3) 199 (52·4) 5·2
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Missed work or activities
In the 4 weeks prior to the survey, 189 (56·7%) of cases
were in full- or part-time employment, 103 (33·5%) of
cases either being retired, students or on home duties,
38 (11·1%) of cases were too young to attend school,
and the rest were either unemployed or unable to
work. Gastroenteritis had a considerable impact on
cases’ work, school and recreational activities in the
survey, with 230 (68·9%) reporting that their illness
interfered with daily activities for a median of 1 day.
Forty-seven of the 230 respondents were answering
on behalf of their child. Seventy-nine (23·3%) cases
reported missing at least 1 day of paid work in the 4
weeks prior to the interview, the median being 2
days (range 1–28 days) missed for their own illness.
Twenty-nine (7·1%) cases reported that someone else
cared for them (13 respondents) or their child (16
respondents), and missed a median of 2 days (range
1–21 days) paid employment of the carers.
Based on these results, gastroenteritis results in an
estimated 13·1 million (95% CI 6·7–19·5) missed
days of productivity in Australia annually. This com-
prised 8·7 million (95% CI 5·2–12·2) missed days of
employment for people with their own illness, and
4·4 million (95% CI 1·5–7·4) missed days of employ-
ment for people who cared for someone else experien-
cing gastroenteritis.
DISCUSSION
Gastroenteritis results in a substantial burden in
Australia with over a million days of lost productivity
each month, either for people suffering from gastro-
enteritis or caring for someone who was ill.
Table 2. Unadjusted and adjusted odds ratios and 95% conﬁdence intervals for 341 cases to visit a doctor by












Diarrhoea 298 46 1·1 (0·4–3·0)
Blood in stool 12 2 1·4 (0·3–7·2)
Stomach cramps 216 28 0·5 (0·2–0·8) 0·3 (0·1–0·6)
Nausea 225 37 2·2 (1·0–4·9)
Loss of appetite 256 43 3·4 (1·0–10·7)
Fever or chills 151 34 3·2 (1·7–6·2) 2·5 (1·5–5·2)
Muscle/body aches 135 24 1·9 (1·0–3·6)
Headache 142 23 0·8 (0·4–1·6)
Stiff neck 51 10 0·9 (0·4–2·3)
Respiratory symptoms 87 26 3·6 (1·8–7·0) 2·3 (1·0–5·4)
Earache 22 10 3·2 (1·2–8·1) 2·7 (0·7–9·8)
Vomiting 161 32 1·6 (0·9–2·9)
Gastroenteritis duration
1–2 days 215 18 Reference
3–4 days 75 19 5·3 (2·6–10·8) 4·2 (1·9–9·2)
55 days 51 15 5·2 (2·0–13·5) 6·1 (2·3–16·4)
OR, Odds ratio; CI, conﬁdence interval.
* Final model after backward stepwise logistic regression for signiﬁcant variables, with stomach cramps, fever or chills, res-
piratory symptoms, earache, and duration of illness remaining in ﬁnal model.
Table 3. Number and proportion of cases taking
medication for symptoms of gastroenteritis and median




















Antidiarrhoeal 64 (15·5) 2 2·1 (1·4–2·8)
Painkiller 68 (15·6) 2 3·4 (2·5–4·3)
Anti-nausea 29 (7·1) 2 1·3 (0·7–1·9)
Anti-cramps 11 (2·1) 3 0·4 (0·05–6·5)
Antibiotics 8 (1·8) 8 0·5 (0·06–1·0)
CI, Conﬁdence interval.
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Additionally, there were an estimated 2·7 million
gastroenteritis-related medical consultations each
year in Australia. Disease-associated medication
usage, consultation of doctors and lost daily activities
are considerable.
The BEACH dataset on General Practice consulta-
tions (Bettering the Evaluation of Care of Health)
shows that gastroenteritis is one of the most frequently
managed problems in general practice during 2008/
2009 in Australia [14]. The proportion of cases who
visited health professionals (36·1%) found in this
study was similar to the proportion reported in New
Zealand and France [15, 16], but lower than the pro-
portion observed in a Chinese study [17]. These differ-
ences may reﬂect important differences in the
healthcare system in the studied countries.
We found that approximately 13·4% of people ex-
periencing gastroenteritis visited a doctor for their ill-
ness, suggesting that most cases are mild. Of all the
respondents with gastroenteritis, only 3·1% provided
a stool sample, which is similar to what was reported
in the NGSI study, and these results are within the
range for other high-income countries (2–8%) [8, 18,
19]. Our study also highlights that increasing duration
of gastrointestinal illness was associated with cases
presenting to a doctor. However, the small number
of cases with some characteristics, such as blood in
stool, meant we were unable to detect signiﬁcant asso-
ciations between these variables and cases visiting a
doctor for gastroenteritis.
The percentage of cases taking medication for
gastroenteritis in Australia (37·0%) is similar to New
Zealand, but lower than that reported from France,
Canada, and China [16, 17, 20]. Additionally, only
2·3% cases reported antibiotic usage for their illness,
which is lower than reported from the NGSI study
where about 5% of cases were prescribed antibiotics
for gastroenteritis [21]. However, as the conﬁdence
intervals of these results overlap with the small num-
bers of cases reporting antibiotic usage, comparisons
between the results are uncertain. The relatively low
proportion of cases using antibiotics in our study
may suggest a decrease in systemic antibacterial pre-
scribing rates in Australia. It is appropriate that there
is a low rate of empirical treatment of gastroenteritis
with antibiotics in this country. People with gastro-
enteritis rarely beneﬁt from antibiotic treatment [22],
but antimicrobial therapies are still recommended for
severe bacterial infections causing gastroenteritis.
In this study, we estimated that there are 13·1 mil-
lion days of lost employment due to gastroenteritis
annually. Our estimate is much higher than reported
in the NGSI study, which estimated six million days
of lost paid work due to gastroenteritis in Australia
in 2001 [8]. This may be due to a change to questions
to try to improve this variable, which probably
inﬂuenced the results. While gastroenteritis is often
mild, it leads to substantial lost productivity in terms
of days off work for illness or caring for others. In
Australia, estimated cost of lost productivity of
foodborne illness due to gastroenteritis was responsible
for 68% of all costs in 2004 [23]. Internationally,
cost-of-illness studies have reported that lost prod-
uctivity, including missed paid employment by sick
individuals and employment missed by caregivers,
accounted for the majority of indirect costs of gastro-
enteritis [5, 24].
Our study has several limitations, including the self-
reported nature of the survey. However, similar
symptom-based case deﬁnitions have been used previ-
ously, and therefore, comparison between studies is
possible. The participation rate for the survey (49%)
was less than the previous survey in Australia in
2001, but comparable to that obtained in other recent
cross-sectional surveys [20, 25, 26]. Elderly females
comprised the largest proportion of the respondents
in our study, but we tried to minimize the impact of
the skewed sample by weighting data to the
Australian population to adjust for known difference
between the sample and the target population. Based
on the weighted data, we estimated that there were
approximately 10·5 million employed persons (data
not shown) in Australia during 2008/2009, which is
similar to what was reported in the census data (10·6
million employed people) [27]. Therefore, post-
stratiﬁcation weighting by age/sex/State in our study
should provide comparable estimates to the Aus-
tralian population.
CONCLUSION
Gastroenteritis incurs considerable resource usage,
and substantial costs for employers in Australia. The
indirect costs of gastroenteritis are signiﬁcant, particu-
larly from lost productivity. It is important that we
better understand the determinants of healthcare-
seeking behaviour, medication usage for people with
gastroenteritis, and submission of specimens for test-
ing to address the costs of gastroenteritis. These esti-
mates for Australia have important implications for
addressing the burden of this illness and the impact
on the healthcare system.
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ABSTRACT
Objectives: To estimate the incidence and risk factors
for gastroenteritis-related hospitalisations in older
adults.
Design: Longitudinal cohort study.
Participants: The 45 and Up Study is a large-scale
Australian prospective study of adults aged ≥45 years
(mean 62.7 years) at recruitment in 2006–2009. Self-
reported demographic, health and dietary information
at recruitment from 265 440 participants were linked to
infectious gastroenteritis hospitalisation data.
Outcome measures: We estimated the incidence of
hospitalisation for infectious gastroenteritis, and
calculated HRs using Cox regression, adjusting for
sociodemographic, health and behavioural variables,
with age as the underlying time variable.
Results: There were 6077 incident infectious
gastroenteritis admissions over 1 111 000 person-
years. Incidence increased exponentially with
increasing age; from 2.4 per 1000 (95% CI 2.2 to 2.5)
in individuals aged 45–54 years to 9.5 per 1000 (95%
CI 9.2 to 9.8) in those aged 65+ years. After
adjustment, hospitalisation due to infectious
gastroenteritis was significantly more common in those
reporting use of proton pump inhibitors (HR 1.6, 95%
CI 1.5 to 1.7), and those with poorer self-rated health
(HR 4.2, 95% CI 3.6 to 4.9).
Conclusions: Infectious gastroenteritis results in
hospitalisation of approximately 1% of people
≥65 years old each year. Early recognition and
supportive treatment of diarrhoea in older patients with
poorer self-rated health may prevent subsequent
hospitalisation.
INTRODUCTION
Gastroenteritis is one of the most common
infectious diseases among humans and is a
major cause of mortality in low-income and
middle-income countries, particularly among
children aged <5 years.1 By contrast, the
highest rates of mortality due to gastroenter-
itis in high-income countries occur in the
elderly,2 particularly people aged ≥75 years.3
The elderly are potentially at higher risk of
some enteric infections, due to decreased
gastric acidity, intestinal motility disorders,
and a compromised immune system.4 5
Despite this, the incidence of gastroenteritis
in the elderly living in the community is
lowest of any age group, with one Australian
study estimating the incidence of people
≥65 years old at 0.33 (95% CI 0.24 to 0.42)
episodes per person per year.6
However, older people may experience
more severe symptoms and be more likely to
require hospitalisation than younger
people.6 In Australia, people aged ≥65 years
old were hospitalised with all-cause gastro-
enteritis at a rate of 20.2 per 1000 population
annually between 2009 and 2010.7 In the
USA, hospitalisation due to all-cause gastro-
enteritis increased by ≥50% in all adults and
elder age groups between 1996 and 2007,
with norovirus estimated to be a signiﬁcant
contributor to the high rates among the
elderly.8 Furthermore, the total healthcare
costs for gastroenteritis requiring hospitalisa-
tion are three times higher per adult patient
compared with a child, due to increasing
length of hospital stay and more common
presentation with severe symptoms and
complications.9
Hospitalisation due to infectious gastro-
enteritis imposes a signiﬁcant burden on the
Strengths and limitations of this study
▪ A large population-based cohort study examining
risk factors for hospitalisation due to gastro-
enteritis, with record linkage to multiple
databases.
▪ Prospectively collected data on a range of poten-
tial risk factors and confounders, allowing ana-
lysis of multiple variables.
▪ Self-reported exposure assessment at the
recruitment.
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health system in industrialised countries.10 However, risk
factors among older adults have not been well described.
In this study, our objective was to estimate age-speciﬁc
rates of hospitalisation due to infectious gastroenteritis,




The Sax Institute’s 45 and Up Study is a population-
based cohort which recruited over 267 000 residents in
the Australian state of New South Wales (NSW) who
were aged 45 years and over between January 2006 and
December 2008. Details of the study methods are pub-
lished elsewhere.11 Study participants were randomly
selected from the national health insurance database
(Medicare), and there was oversampling of those living
in rural regions and those aged over 80 years.
Participants completed a questionnaire at recruitment
where they provided information on sociodemographics,
lifestyle, dietary habits and their health (see https://
www.saxinstitute.org.au/our-work/45-up-study/
questionnaires/), and agreed to have their data linked
to other administrative health records.
Questionnaire data from study participants were
linked to the NSW Admitted Patient Data Collection
(APDC) to identify hospitalisations due to infectious
gastroenteritis, and the NSW Register of Births, Deaths
and Marriages (RBDM) for deaths. The NSW APDC
records demographic and episode-related information
for all patient admissions to NSW hospitals, and includes
the principal diagnosis responsible for the admission, up
to 54 additional diagnoses contributing to the admis-
sion, and the date of admission. Clinical information is
coded using the International Classiﬁcation of Disease
V.10 Australian modiﬁcation (ICD-10-AM).12 The NSW
RBDM includes a record of all deaths in NSW and the
date of death. Information on cause of death was not
available at the time of analysis. We had complete APDC
and RBDM records until 30 June 2012. The 45 and Up
Study participant data, APDC and RBDM were linked
independently of the study investigators by the NSW
Centre for Health Record Linkage using personal infor-
mation such as name, date of birth and sex, with false-
positive and false-negative rates of <0.5% and <0.1%,
respectively.13
Case definition
Participants were deﬁned as having an incident hospital-
isation with infectious gastroenteritis if they had a linked
APDC record where the principal or a secondary diag-
nosis was coded with an ICD-10-AM code for either diar-
rhoea of determined aetiology-bacterial (A00-A05),
parasitic (A06-A07), viral (A08) or undetermined
aetiology-presumed infectious disease (A09), and the
admission occurred following recruitment.
A gastroenteritis complication was deﬁned if cases also
had coded in their linked APDC record either ﬂuid,
electrolyte and acid–base disorders (ICD-10-AM E87
excluding ﬂuid overload E87.7); shock (R57, excluding
cardiogenic shock R57.0) or septicaemia (A41.9).
Statistical analysis
Participants who had a linked hospitalisation record for
gastroenteritis in the 30 days prior to recruitment were
excluded, as we wanted to exclude the possibility that
any admissions due to gastroenteritis immediately follow-
ing recruitment may be part of that same episode. To
minimise the impact of pre-existing illness that may pre-
dispose individuals to infectious gastroenteritis, partici-
pants were also excluded if they had a linked
hospitalisation record with a principal diagnosis code
for any of the following: chronic bowel problems (non-
infective enteritis and colitis K50-K52, irritable bowel syn-
drome K58), immunosuppressive disorders (D80-D89),
or cancer (C00-C97) in the 5 years prior to study entry.
Follow-up was calculated from the date of recruitment to
the ﬁrst date of admission for gastroenteritis, death or
the end of database follow-up (30 June 2012), whichever
came ﬁrst. Incident gastroenteritis hospitalisation rates
were calculated according to age (45–54, 55–64, 65–74,
75–84 or ≥85 years), sex, annual household income
(<$A20 000, $A20 000–$A29 999, $A30 000–$A39 999,
$A40 000–$A49 999, $A50 000–$A69 999, $A70 000 or
more per year, or unknown), and region of residence
(cities, inner regional or outer regional/remote/very
remote) based on the Accessibility/Remoteness Index of
Australia.14
HRs for hospitalisations due to gastroenteritis by socio-
demographic, behavioural and health status variables
were estimated using Cox proportional hazards models
with age as the underlying time variable.15 Regression
models were adjusted for attained age (as this was the
underlying time variable) and sex. Models were then
adjusted for additional variables, including annual
household income, region of residence, education (3
categories: university degree or higher, no university
degree, or unknown), health status variables including
self-rated health (excellent, very good, good, fair, poor
or unknown), and body mass index (BMI: underweight
(<18.5 kg/m2), normal (18.5–24.99 kg/m2), overweight
(25–29.99 kg/m2), obese (≥30 kg/m2) or unknown),
smoking (current, past, never or unknown), alcohol
(none, 1–2 alcoholic drinks per day, >2 alcoholic drinks
per day or unknown) and factors which have been previ-
ously identiﬁed as risk factors for gastroenteritis, includ-
ing living in aged care facilities (yes, no or unknown),
proton pump inhibitors (PPIs) usage (yes, no), fre-
quency of chicken/poultry intake (none, at least once
per week or unknown), frequency of seafood intake
(none, at least once per week or unknown), egg con-
sumption (ever, never), and fruit and vegetable intake
(low, adequate or unknown). Fruit and vegetable intake
was categorised as ‘low’ if fruit intake was less than two
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servings daily, or vegetable intake was less than ﬁve ser-
vings daily, and ‘adequate’ if fruit intake was at least two
servings daily and vegetable intake at least ﬁve servings
daily. Participants were classiﬁed as using PPIs if they
answered yes to the question ‘Have you taken any medi-
cations, vitamins or supplements for most of the last 4
weeks?’, and crossed out either ‘Nexium’, ‘Somac’ or
‘Losec, Acimax omeprazole’ in the baseline question-
naire. Participants were classiﬁed as not using PPIs if
they answered ‘no’ to the above question, or answered
‘yes’ to the above question but did not cross out any one
of the above medications.
Missing values for variables were coded as separate cat-
egories in the model. The proportionality assumption
was examined by plotting the Schoenfeld residuals
against the time variable in each model.16 Where this
assumption was violated, we stratiﬁed exposure variables
and compared ﬁndings under the two models.
Sensitivity analyses were conducted by deﬁning cases as
only those with a principal hospital diagnosis of infec-
tious gastroenteritis, and also including participants with
a hospitalisation for chronic bowel problems, immuno-
suppressive disorders and cancer as a principal diagno-
sis, before recruitment. All analyses were carried out
using STATAV.12.1.
RESULT
After excluding participants with a linked infectious
gastroenteritis hospitalisation record 30 days prior to
recruitment (n=45), participants with prior hospitalisa-
tions for speciﬁc illnesses associated with hospitalisations
due to gastroenteritis (n=706), and conﬁrmed linkage
errors (n=44), there were 265 440 participants in the
analysis, yielding a total of 1 111 223 years of follow-up
(median 3.9 years per person). The mean age of study
participants at recruitment was 62.7 years (SD 11.2), and
53.6% were women.
There were 6077 (2.3%) participants with at least one
linked incident infectious gastroenteritis hospitalisation
record during follow-up, of which 53.7% (3261/6077)
had infectious gastroenteritis as the primary reason for
admission (see online supplementary table S1). Among
the 6077 participants with hospitalisation due to
incident-infectious gastroenteritis, 58.6% (3560/6077)
were referred to the hospital from the emergency
department, and 26.8% (1631/6077) from a medical prac-
titioner. The remaining cases were referred from a range
of other sources, including community health, residential
care and other hospitals. The mean length of hospital stay
for the ﬁrst hospitalisation among those 6077 participants
admitted was 7.5 (SD 17.4) days; median length 3 days.
Complications of gastroenteritis were reported in 11.0%
(667/6077) of the hospitalisations due to gastroenteritis.
Both the length of stay and the proportion with complica-
tions increased with increasing age (table 1). Among
cases, 2.6% (160/6077) of the patients died within 30 days
of hospital admission. Participants aged ≥65 years
accounted for the majority of these deaths (90.6%,
n=145) (table 1).
The crude incidence of hospitalisations due to gastro-
enteritis in the cohort was 5.5 per 1000 person-years (95%
CI 5.3 to 5.6), which differed by age, sex, household
income and region of residence. Incidence rose from 2.4
hospitalisations per 1000 (95% CI 2.2 to 2.5) person-years
in individuals aged 45–54 years to 21.8 per 1000 (95% CI
20.2 to 23.6) in those aged 85+ years (p<0.001 for linear
trend) (table 2). The rate of hospitalisations due to gastro-
enteritis was higher in women than in men (5.8 and 5.0
per 1000 person-years, respectively), but for both sexes,
hospitalisation rates increased with decreasing household
income (p<0.001). Rates were also greater among those
living in cities than in other regions (6.1, 4.9 and 5.1 per
1000 person-years, respectively, in those living in cities,
inner regional, outer regional; p=0.01) (table 2).
After full adjustment, participant sex, self-rated health,
BMI and use of PPIs remained signiﬁcantly associated
with hospitalisation due to gastroenteritis (ﬁgure 1).
The adjusted HRs (aHR) increased signiﬁcantly with
poorer self-reported health with risks >300% greater for
those with poor versus those with excellent health (aHR
4.18, 95% CI 3.61 to 4.84). Hospitalisation due to infec-
tious gastroenteritis was signiﬁcantly more common in
those reporting PPIs use (aHR 1.57, 95% CI 1.48 to
1.66). Compared with participants with a healthy BMI,
the risk was signiﬁcantly higher in the underweight
(aHR 1.22, 95% CI 1.02 to 1.47) and the obese (aHR
1.08, 95% CI 1.01 to 1.15). We did not observe signiﬁ-
cant associations between hospitalisations due to gastro-
enteritis and food consumption, including fruit and
vegetable intake, chicken/poultry intake, egg consump-
tion and seafood consumption (ﬁgure 1).
Table 1 Proportion of total complications of gastroenteritis, and mean length of hospital stay by age group, 45 and Up Study
Age group (years) Complications Cases
Complications/
cases (%)
Mean length of hospital
stay (days) (SD)
Death within 30 days
of admission
45–54 56 785 7.1 4.0 (11.9) 4 (2.5)
55–64 118 1347 8.8 5.8 (15.3) 11 (6.9)
65–74 134 1484 9.1 6.2 (10.2) 25 (15.6)
75–84 260 1829 14.2 9.6 (15.8) 81 (50.6)
≥85 99 632 15.7 12.5 (34.5) 39 (24.4)
Total 667 6077 11.0 7.5 (17.4) 160
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Examining PPIs usage, we identiﬁed potential con-
cerns with the proportionality assumption, however, a
comparison of ﬁndings with a stratiﬁed version of the
variable reassured us that PPIs usage could be included
in the ﬁnal Cox model unaltered (data not shown).
There were 3261 hospitalisations due to gastroenter-
itis, where a gastrointestinal infection code occurred in
the principal hospital diagnosis ﬁeld (see online supple-
mentary table S1). Overall results were generally similar
to the broader deﬁnition, with the rates of hospitalisa-
tions due to gastroenteritis increasing with increasing
age (p<0.001 for linear trend). Male sex was signiﬁcantly
related to a reduced risk (aHR 0.75, 95% CI 0.69 to
0.81). Poorer self-rated health (aHR 3.45, 95% CI 2.80
to 4.26), obesity (1.12, 95% CI 1.02 to 1.22) and PPIs
use (1.74, 95% CI 1.61 to 1.89) were all related to an
increased risk of hospitalisations due to gastroenteritis.
The sensitivity analysis, including cases with a linked
record of hospital admission with pre-existing illness,
showed little change in the HRs (n=266 146; 6783 inci-
dent hospitalisations due to gastroenteritis since base-
line; see online supplementary table S2).
DISCUSSION
In this large population-based prospective study, hospi-
talisation due to infectious gastroenteritis was extremely
common. We estimate that 1% of people aged
≥65 years old were hospitalised annually with gastro-
enteritis, and accounted for more than two-thirds of
gastroenteritis-related complications. The incidence
and length of hospital stay increased dramatically with
increasing age. After adjustment, females, adults with
poor general health, and those taking PPIs had a
greater risk of being hospitalised with gastroenteritis.
The high rate of hospitalisations due to gastroenteritis
in the elderly is consistent with increased rates of hospi-
talisation for infectious disease in this age group,7 17
although the rate in people aged ≥65 years old was
lower than a previous study examining hospitalisations
due to gastroenteritis nationally due to all causes.7 This
may reﬂect differences in study design and case deﬁni-
tions. In particular, the national study included admis-
sion codes for conditions that were not necessarily
infectious in nature, whereas, we attempted to include
only infectious causes. The trend of increasing hospitali-
sations with age in our study is likely to be due to
greater severity of illness in older patients,18 and the
increasing likelihood of severe consequences, such as
dehydration, electrolyte imbalance and exacerbation of
chronic conditions.19
Differences by sex were noted for hospitalisations due
to gastroenteritis in all age groups. The pattern was pre-
viously reported in a US study, which used nationally
representative data to investigate the trend of hospitalisa-
tions due to infectious disease for all ages.20 One pos-
sible explanation for the higher rate in females may be
inadequate family support and social care for older
women, possibly resulting in greater use of hospital ser-
vices. In this study, we observed a higher proportion of





Age group (years) <0.001
45–54 77 669 785/332 330 2.4 (2.2 to 2.5)
55–64 85 487 1347/363 217 3.7 (3.5 to 3.9)
65–74 57 678 1484/241 404 6.1 (5.8 to 6.5)
75–84 36 470 1829/145 330 12.6 (12.0 to 13.2)
≥85 8136 632/28 941 21.8 (20.2 to 23.6)
Sex <0.001
Female 142 313 3479/596 317 5.8 (5.6 to 6.0)
Male 123 127 2598/514 905 5.0 (4.9 to 5.2)
Household income ($A/year) <0.001
<$A20 000 52 051 1855/214 088 8.7 (8.3 to 9.1)
$A20 000–$A29 999 25 403 655/106 717 6.1 (5.7 to 6.6)
$A30 000–$A39 999 21 005 433/88 693 4.9 (4.4 to 5.4)
$A40 000–$A49 999 19 156 324/80 931 4.0 (3.6 to 4.5)
$A50 000–$A69 999 27 751 397/117 755 3.4 (3.1 to 3.7)
$A70 000 or more 62 605 655/263 829 2.5 (2.3 to 2.7)
Unknown 57 469 1758/239 205 7.4 (7.0 to 7.7)
Region of residence 0.01
Cities 119 449 3012/497 142 6.1 (5.8 to 6.3)
Inner regional 93 299 1932/392 057 4.9 (4.7 to 5.2)
Outer regional/remote/very remote 52 692 1133/222 023 5.1 (4.8 to 5.4)
Total 265 440 6077/1 111 223 5.5 (5.3 to 5.6)
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female cases (62%) having an additional diagnosis
coded with an ICD-10-AM for living alone (Z60.2), inad-
equate family support (Z63.2) and absence of a family
member (Z63.3), than male cases (38%) at the time of
admission, which may indicate an inadequate care of
female patients in our study.
Self-rated health has previously been reported as a
signiﬁcant predictor of severe health outcomes, such
as mortality.21 Although mortality remains the stron-
gest biological indicator of ill-health, disease-related
hospitalisation captures the direct burden of illness. In
our study, participants’ responses to questions about
self-rated health demonstrated a strong association
with hospitalisations due to gastroenteritis. Consequently,
poor self-rated health may serve as a useful marker for
people at higher risk of hospitalisation who present to
family physicians with gastroenteritis. Similarly, people
with a very high or very low BMI were at higher risk of
hospitalisation with gastroenteritis. These ﬁndings high-
light the importance of general health in affecting hospi-
talisation with gastrointestinal infection in older adults.
We identiﬁed an association between PPIs use and
hospitalisation with gastroenteritis, which has been con-
sistently shown in previous studies investigating risk
Figure 1 Associations between various baseline characteristics and incident infectious gastroenteritis hospitalisations, the 45
and Up Study (BMI, body mass index).
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factors for gastrointestinal infections.22 23 Treatment
with PPIs lowers gastric acidity, which is a ﬁrst line of
defence against ingested pathogens, leading to bacterial
colonisation, thus increasing an individual’s susceptibil-
ity to enteric infection.24 A recent study examining the
incidence of Salmonella and Campylobacter infection in
patients prescribed PPIs argued that such people were
already at higher underlying risk of enteric infection
before prescription.25 In our study, PPIs use was self-
reported at recruitment, and was signiﬁcantly associated
with later hospitalisation for gastroenteritis even after
adjusting for self-rated health at baseline. Although our
study was insufﬁcient to establish a causal relationship,
this adds to the evidence that PPIs are associated with
hospitalisation involving enteric infection.
We investigated the possible association between food
consumption history and the risk of gastroenteritis, but
did not observe any association between frequency of
fruit and vegetable intake, chicken and poultry, seafood
or eggs, and risk of hospitalisations due to infectious
gastroenteritis. This may be due to the nature of the
baseline questionnaire that did not collect detailed
dietary information of participants. For example, in the
questionnaire, participants were only asked if they ever
eat eggs, and did not collect information on frequency
of egg consumption. Additionally, our study captures
cases of gastroenteritis due to a range of aetiological
agents, so it is not surprising that foods were not import-
ant risk factors. Campylobacter spp and Salmonella spp are
commonly found in adult patients hospitalised with
infectious gastroenteritis,26 although viral enteritis has
also been identiﬁed as a key cause of seasonal increases
in hospitalisation among the elderly.27
Our study has several limitations that may inﬂuence
the interpretation of results. First, risk factors were
reported at the time of recruitment, and may have
changed between recruitment and hospitalisation.
Second, exposure assessment was based on self-report.
Dietary intake can be difﬁcult to measure, despite self-
report being reasonably reliable for some factors.28 29
However, a validation study involving the short questions
related to diet used in the 45 and Up Study question-
naire has shown them to be reproducible over time.30
Third, the 45 and Up study cohort, while including
about 1 in 10 adults in the age range in NSW, is likely to
be more health conscious than the general NSW popula-
tion, hence, the rates of hospitalisations due to gastro-
enteritis may be underestimated, although this would be
unlikely to affect within-cohort comparisons, such as the
estimates of HRs.31
CONCLUSION
Our results highlight a substantial burden to the health-
care system from gastroenteritis in an aging population.
Future efforts should focus on deﬁning and improving
preventive measures for hospitalisations due to gastro-
enteritis among the elderly. Early recognition and
supportive treatment of diarrhoea in older patients with
poorer self-rated health may prevent subsequent hospi-
talisation. Additionally, further research is required to
examine if PPIs use results in excess hospitalisations due
to gastroenteritis and speciﬁc enteric infections, as it is a
potentially modiﬁable risk factor.
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Use of Proton Pump Inhibitors and the Risk of
Hospitalization for Infectious Gastroenteritis
Yingxi Chen1, Bette Liu2, Kathryn Glass1, Wei Du1, Emily Banks1,3, Martyn Kirk1*
1 The Australian National University, Canberra, ACT, Australia, 2 University of New South Wales, Sydney,




To quantify the association between PPI use, type and dose and infectious gastroenteritis
hospitalization in a population-based cohort of middle-aged and older adults.
Methods
Prospective study of 38,019 concession card holders followed up over 6 years in the Sax
Institute’s 45 and Up Study. Data from the baseline questionnaire were linked to prescription
medication, hospitalization, notifiable disease, cancer registry and death datasets from
2006–2012. Associations between PPI use and gastroenteritis hospitalization were exam-
ined using Cox regressions with age as the underlying time variable.
Results
Among 38,019 participants, the median age was 69.7 years, and 57.3% were women. Com-
pared to non-users, current PPI users were more likely to be older, and have a higher BMI.
During follow-up there were 1,982 incident gastroenteritis hospitalizations (crude rate: 12.9
per 1000 person-years, 95% CI: 12.3–13.5). PPI use was significantly associated with infec-
tious gastroenteritis hospitalization (aHR 1.4, 95% CI: 1.2–1.5). Among current users, a
dose-response relationship was observed between the average daily dose (DDD) dispensed
per day and infectious gastroenteritis hospitalization (Ptrend<0.001). We also observed higher
rates of infectious gastroenteritis hospitalization and greater PPI use among participants with
a history of chronic bowel problems (aHR 2.2, 95% CI: 1.9–2.5). There was no difference in
risk by type of PPI. Recent use of H2 receptors was not associated with gastroenteritis
hospitalization.
Conclusion
PPI use is associated with an increased risk of infectious gastroenteritis hospitalization.
Clinicians should be aware of this risk when considering PPI therapy.
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Introduction
Proton pump inhibitors (PPIs), introduced in 1989, are the most potent gastric acid suppres-
sants available [1]. They are widely used by both gastroenterologists and primary care physi-
cians in the effective treatment of acid-related disorders. PPIs are one of the most commonly
prescribed medications worldwide [2], although it has been suggested that 25–70% of patients
taking PPIs lack appropriate indications [2]. In Australia, there are five PPIs listed on the Phar-
maceutical Benefits Scheme (PBS)—a national government system that subsidizes the cost of
medicines, most of which are dispensed by pharmacists. Omeprazole and lansoprazole were
first introduced onto the PBS in 1994, followed by pantoprazole in 1995, rabeprazole in 2001
and esomeprazole in 2002. Since their introduction, PPI use in Australia has grown dramati-
cally [3]. In the 2013–14 financial year, physicians issued over 19 million prescriptions for
PPIs with the most commonly prescribed type of PPI costing the PBS over $200 million [4].
Many patients take PPIs on a continuous or long-term basis [5]. Although this class of drug
is considered safe and has been approved for long-term use [6], concerns have been raised
regarding associated adverse effects [7]. Studies have reported that PPIs are associated with
serious adverse events, including kidney diseases, hip fracture, community-acquired pneumo-
nia, and Clostridium difficile infection [8–11]. PPIs irreversibly inactivate the gastric H+/K+-
ATPase pump and cause a profound inhibition of gastric acid secretion [12, 13]. Significant
hypochlorhydria, particularly among the elderly population who may have decreased clearance
of PPIs, could result in bacterial overgrowth [14] and potentially increase susceptibility to
infection. PPI use has also been shown to reduce gut commensal load and microbial density
[15].
Although PPIs can potentially impair gastrointestinal host defenses, the association between
PPI use and enteric infections has only recently been explored systematically [16, 17]. Observa-
tional studies have found increased risks of Campylobacter, Salmonella and C. difficile infection
[9, 18]. However, the effects of different types and doses of PPIs remain unknown. Addition-
ally, to our knowledge, no population-based studies have evaluated the effect of different PPI
dosage and infectious gastroenteritis hospitalization among patients with chronic bowel prob-
lems. Given that older adults constitute the majority of PPI users [3, 19], the aim of this study
was to investigate the association between PPI use and hospitalization for infectious gastroen-
teritis, considering both dose and type of PPIs, in a large prospective study of adults aged 45
years and older with and without a history of chronic bowel problems.
Methods
Data sources and study population
The Sax Institute’s 45 and Up Study is an Australian cohort of 267,153 men and women aged
45 years and over from New South Wales (NSW), the most populous state in Australia. The 45
and Up Study cohort were randomly selected from the Medicare Australia (now the Depart-
ment of Human Services) enrolment database. Baseline questionnaires were distributed from
1 January 2006 to 31 December 2008. Participants joined the study by completing the baseline
questionnaire and giving consent for follow-up through repeated data collection and linkage
of their data to multiple population health databases. Baseline questionnaire data include
information on socio-demographics, general health and behavior. The study is described in
detail elsewhere [20], and questionnaires can be accessed at http://www.45andup.org.au.
For this report we linked individual participant baseline data to prescription medication,
hospitalization, notifiable disease, cancer registrations and death datasets. Specifically, the 45
and Up Study baseline questionnaire data were linked to medication data from the PBS
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records to obtain medication use at baseline and during follow-up. Questionnaire data were
linked to hospitalization data from the NSW Admitted Patient Data Collection (APDC) to
identify cases of infectious gastroenteritis and to capture participants with previous hospitali-
zations. In order to identify cases of Salmonella infection, which is a notifiable disease in NSW,
baseline data were linked to the Notifiable Conditions Information Management System
(NCIMS). Data were then linked to death data to ascertain fact and date of death for censoring
purposes. Baseline data were also retrospectively linked to cancer registry data from the NSW
Central Cancer Registry (CCR) to identify participants who had a cancer diagnosis before
recruitment. The NSW Centre for Health Record Linkage performed the data linkage indepen-
dent of the study investigators and report false positive and false negative linkages of<0.5%
and<0.1%, respectively [21].
The PBS dataset is an administrative dataset documenting information about subsided dis-
pensed prescription drugs including PPIs for the Australian population [22]. For medicines
listed on the PBS, consumers contribute a copayment towards the cost, and the Australian
Government pays the remainder. People with a concession card pay a smaller copayment
(AUD 6 in 2014) than the general population. Concession card holders are people with a Pen-
sioner Concession Card, a Commonwealth Seniors Health Card or a Health Care Card. The
PBS captured all medicines dispensed to concession card holders in the time period covered
by these analyses.
The NSW APDC dataset is a complete census of all hospital admissions in NSW. The prin-
cipal diagnosis for each admission, and up to 54 additional diagnoses contributing to the
admission were coded using the International Classification of Diseases, 10th revision, Austra-
lian Modification (ICD-10-AM) [23]. The NCIMS database contains a record of Salmonella
infections in NSW, including the estimated onset date and the type of laboratory specimen
used for confirmation. The NSW CCR is a population-based registry that records all new diag-
noses of cancer in NSW residents and all deaths from cancer.
Measurements
Case definition. The primary outcome of interest was hospitalization with infectious gas-
troenteritis, which was defined as a participant with an index linked hospitalization record
where the principal or a secondary diagnosis was coded with an ICD-10-AM code for intesti-
nal infectious diseases (A00-A09) following study recruitment.
Secondary outcomes included Salmonella-, Campylobacter- and C. difficile infection. A case
of Salmonella infection was defined as a participant who had a linked notification record of
non-typhoidal Salmonella infection during follow up. A case of Campylobacter-, or C. difficile
infection was defined as a participant who had a linked hospitalization record with diagnosis
of Campylobacter enteritis (ICD-10-AM code A04.5), or C. difficile colitis (A04.7) during fol-
low up, respectively.
Definition of PPI use. PPI use was identified using linked records on dispensing from
the PBS dataset with Anatomical Therapeutic Chemical (ATC) classification codes begin-
ning with A02BC, proton pump inhibitors (World Health Organization Collaborating Cen-
tre for Drug Statistics Methodology, 2013) [24]. Study participants were categorized as
current PPI users, former users and non-users. Current users were defined as those who
had at least one PPI dispensing record within the 3 months prior to recruitment. Former
users were defined as participants who had at least one PPI dispensing record in a period of
3–12 months prior to recruitment. Non-users were defined as participants who were not
dispensed any PPIs over the period prior to recruitment that we had PBS records for, or
who had a PPI dispensed 12 months prior to recruitment.
PPI Use and Risk of Gastroenteritis
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Current users were further categorized by type of PPI and dose. Types of PPIs used included
omeprazole (ATC codes: A02BC01), pantoprazole (A02BC02), lansoprazole (A02BC03), rabe-
prazole (A02BC04), esomeprazole (A02BC05) or more than one type. Dose was described as
the average number of dispensed DDD per day during the 3 months prior to recruitment [25].
DDD is a World Health Organization classification system which is defined as ‘the assumed
average maintenance dose per day for a drug used for its main indication in adults’ [26]. To obtain
the average number of dispensed DDD per day, we firstly calculated the total number of dis-
pensed DDD for each PPI, which was calculated as the strength (mg) of the dispensed PPI mul-
tiplied by the pack size and the number of dispensed packs, and then divided by the DDD of
that PPI. This dispensed DDD was then summed for each participant and divided by the dura-
tion of use (3 months) to obtain the average dispensed DDD per day during the 3 months prior
to the recruitment.
Definition of covariates. Socio-demographic factors and health status characteristics
obtained from the baseline questionnaire included: age (grouped as 45–54, 55–64, 65–74 or
75 years), sex, body mass index (BMI:<18.5, 18.5–24.9, 25–29.9 or30 kg/m2), self-rated
health (excellent, good, fair or poor), smoking (current, past or never) and alcohol intake (none,
1–2 alcohol drinks per day or>2 alcohol drinks per day). Region of residence was obtained
from Medicare Australia using address at time of recruitment, grouped as cities, inner regional
or outer regional/remote based on the Accessibility/Remoteness Index of Australia [27].
History of cancer diagnosis, excluding non-melanoma skin cancer, in the 5 years prior to
recruitment (yes, no) was ascertained by linkage to the CCR. History of chronic bowel prob-
lems (yes, no), was ascertained by linkage to an APDC record with an ICD-10-AM diagnosis
code of K50 to K52 (non-infective enteritis and colitis) and K58 (irritable bowel syndrome) in
any of the 55 diagnostic fields in the 6 years prior to recruitment. Recent H2 receptor antago-
nist and antibiotic use were defined based on the PBS dispensing records (ATC codes:
A02BA01, A02BA02, A02BA03, A02BA04 for H2 receptors and J01 for antibiotics) in the 3
months before recruitment.
Statistical methods
In this study, complete records of dispensed PPIs were only available for people with a valid
healthcare concession-card [25]. Therefore, analyses were restricted to 45 and Up Study partic-
ipants who were concession-card holders. Additionally, participants were excluded from the
analyses if they had missing data on date of entry into the study, or missing PBS data on dis-
pensing. Follow-up was calculated from the date of recruitment to the index date of admission
for infectious gastroenteritis, death, or the last date for which database records were available
(30 June 2012), whichever came first. Rates of infectious gastroenteritis hospitalizations since
baseline and 95% confidence intervals (CIs) were calculated for PPI current users, former
users and non-users at baseline.
Characteristics of PPI current users, former users and non-users were firstly compared
using chi-squared tests. For the main analysis to examine the risk of PPI use and infectious gas-
troenteritis, Kaplan-Meier analysis with the log-rank test was first used to determine the prob-
ability of hospitalization with infectious gastroenteritis for current users, former users and
non-users. Cox proportional hazards regression with age as the underlying time variable was
then used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs). Regression
models were initially adjusted only for age (as this was the underlying time variable) and sex,
and then further adjusted for region of residence, self-rated health, BMI, cancer in previous 5
years, history of chronic bowel problems, recent H2 receptor antagonist use, and recent antibi-
otic use. Finally, smoking and alcohol intake were also added to the model.
PPI Use and Risk of Gastroenteritis
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In current users, the risk of infectious gastroenteritis hospitalization was further evaluated
according to type and dose of PPIs. To examine the potential impact of chronic bowel prob-
lems on the association between PPI use and infectious gastroenteritis, models were then strat-
ified by history of chronic bowel problems. Similar analyses were performed for the secondary
outcomes of Salmonella-, Campylobacter-, and C. difficile infection, respectively.
The proportionality assumption of the Cox regression models were verified by plotting the
Schoenfeld residuals against the time variable in each model, with the time-dependent form of
the model used where covariates displayed non-proportionality of hazards. No violations were
detected for PPI use. Significant violation was observed for recent antibiotic use, and this
covariate was included as a time-dependent form in the models.
Sensitivity analysis was conducted by restricting cases to only those with a principal hospital
diagnosis of infectious gastroenteritis. To examine the effects of changes in PPI use over time a
second sensitivity analysis was conducted by restricting the study population to participants
who remained in the same PPI use category during follow-up. We then conducted a third sen-
sitivity analysis using a time-dependent Cox model with time-varying PPI ever-use. All analy-
ses were carried out using STATA 12.1.
Ethics approval
The conduct of the 45 and Up Study was approved by the University of New South Wales
Human Research Ethics Committee. Ethics approval for this study was obtained from the
NSW Population and Health Services Research Ethics Committee, and the Australian National
University Human Research Ethics Committee. All participants provided written informed
consent.
Results
After restricting participants to those with concessional-only PBS records during the study
period (n = 38,074), and excluding those who had missing data on date of entry into the study
(n = 10), or missing PBS data on dispensing (n = 45), there were 38,019 participants, who were
followed from baseline for a median of 3.9 years, yielding a total of 153,997 person-years of fol-
low-up. The median age of study participants at recruitment was 69.7 years (interquartile
range: 63.3–77.4), and 57.3% were women.
Table 1 summarizes the characteristics of the study population. Overall, 52.1% (n = 19,787)
of participants had been dispensed at least one PPI in the 3 months prior to recruitment (cate-
gorized as PPI current users), 38.8% (n = 14,762) were defined as non-users, of which 18.8%
(n = 2,771) had a record of PPI use12 months before recruitment. PPI current users were
more likely to be older and have a higher BMI compared to non-users. Participants taking H2
receptor antagonists had similar characteristics to participants taking PPIs (Table 1).
Among users, esomeprazole was the most frequently dispensed PPI (n = 5,950; 30.1%), fol-
lowed by omeprazole (n = 4,983; 25.2%) and pantoprazole (n = 4,235; 21.4%). Most users had
used only one type of PPI (n = 19,096; 96.1%).
There were 1,982 cases of incident infectious gastroenteritis hospitalization during follow-
up. The crude incidence of gastroenteritis hospitalization in the cohort was 12.9 per 1,000 per-
son years (95% CI, 12.3–13.5). Compared to non-users, the adjusted relative risk of hospitaliza-
tion was significantly higher in current PPI users (aHR 1.4, 95% CI: 1.2–1.5) and former users
(aHR 1.2, 95% CI: 1.1–1.5) (Fig 1). Recent use of prescribed H2 receptors was not associated
with hospitalization for infectious gastroenteritis (aHR 0.9, 95% CI: 0.7–1.1). Participants with
a history of cancer or chronic bowel problems were more likely to be hospitalized with infec-
tious gastroenteritis (aHR 1.5, 95% CI: 1.3–1.7; and 2.2, 95% CI: 1.9–2.5, respectively).
PPI Use and Risk of Gastroenteritis
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Among current users, a dose-response relationship was observed between the average number
of DDD dispensed per day and risk of infectious gastroenteritis hospitalization (Ptrend<0.001),
with a 60% increase in risk among those dispensed>1 DDD/day versus non-use (aHR 1.6, 95%
CI: 1.3–1.8). The risk did not differ significantly by PPI type (Table 2). The dose response effect
was consistent when analyses were restricted to participants with a history of chronic bowel prob-
lems; compared to non-users, aHRs of infectious gastroenteritis hospitalization were 1.2 (95% CI:
0.8–1.9) in participants with a dose0.5DDD/day, 1.7 (95% CI: 1.2–2.2) with a dose of 0.5-
1DDD/day, and 2.0 (95% CI: 1.4–2.8) with a dose>1DDD/day (Ptrend<0.001) (Table 2).
The broad relationships between PPI use and the risk of specific types of infectious gastro-
enteritis—C. difficile, Salmonella and Campylobacter infection—did not differ materially from
that observed for infectious gastroenteritis hospitalization overall. Risks were significantly





(n = 3,470) (%)
PPI current users
(n = 19,787) (%)
H2 receptor users
(n = 1,951) (%)
P-
value*
Age (years) P < .001
45–54 1,564 (10.6) 366 (10.6) 1,376 (6.9) 152 (7.8)
55–64 3,440 (23.3) 728 (21.0) 4,102 (20.8) 384 (19.6)
65–74 5,503 (37.3) 1,354 (39.0) 7,517 (38.0) 729 (37.4)
75 4,255 (28.8) 1,022 (29.4) 6,792 (34.3) 686 (35.2)
Female sex 8,336 (56.5) 2,043 (58.9) 11,408 (57.6) 1,136 (58.2) P = .3
Region of residence P = .03
Cities 5,898 (39.9) 1,488 (42.8) 7,898 (39.9) 881 (45.1)
Inner regional 5,467 (37.1) 1,245 (35.9) 7,568 (38.3) 646 (33.1)
Outer regional/remote 3,397 (23.0) 737 (21.3) 4,321 (21.8) 424 (21.7)
History of chronic bowel
problems
692 (4.7) 249 (7.2) 1,752 (8.9) 158 (8.1) P < .001
Self-rated health P < .001
Excellent 4,919 (33.3) 1,053 (30.4) 4,670 (23.6) 422 (21.6)
Good 5,484 (37.2) 1,258 (36.3) 7,569 (38.3) 698 (35.7)
Fair 2,961 (20.1) 765 (22.1) 5,108 (25.8) 531 (27.2)
Poor 656 (4.4) 192 (5.5) 1,436 (7.3) 177 (9.1)
Cancer in previous 5 years 1,184 (8.0) 299 (8.6) 1,760 (8.9) 155 (7.9) P = .03
BMI (kg/m2) P < .001
<18.5 233 (1.7) 63 (1.9) 288 (1.6) 25 (1.4)
18.5–24.9 4,682 (34.5) 1,127 (35.5) 5,252 (28.9) 601 (33.5)
25–29.9 5,125 (37.7) 1,164 (36.7) 6,999 (38.6) 633 (35.3)
>30 3,550 (26.1) 818 (25.9) 5,576 (30.8) 535 (29.8)
Smoking P < .001
Never 7,610 (51.9) 1,829 (53.0) 10,195 (51.8) 1,021 (52.9)
Current 1,457 (9.9) 311 (9.1) 1,375 (7.0) 158 (8.2)
Past 5,599 (38.2) 1,308 (37.9) 8,079 (41.2) 751 (38.9)
Alcohol intake P < .001
None 6,349 (43.0) 1,534 (44.2) 9,053 (45.7) 955 (48.9)
2 units/day 6,211 (42.1) 1,431 (41.2) 7,951 (40.2) 718 (36.8)
> 2 units/day 1,644 (11.1) 354 (10.2) 2,104 (10.6) 186 (9.5)
P-value*: Chi-squared test for PPI category. Missing: self-rated health = 1,948 (5.1%); BMI = 3,142 (8.2%); smoking = 256 (0.6%); alcohol intake = 1,388
(3.6%)
doi:10.1371/journal.pone.0168618.t001
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elevated for C. difficile infection among PPI current users (aHR: 1.5, 95% CI: 1.1–2.1). Com-
pared to non-users, participants dispensed >1 DDD/day were 120% more likely to have C. dif-
ficile infection (aHR: 2.2, 95% CI: 1.4–3.4), and 100% more likely to have Salmonella infection
Fig 1. Crude incidence and hazard ratios of participants admitted to hospital with infectious gastroenteritis
according to Proton Pump Inhibitor (PPI) user categories and other characteristics.
doi:10.1371/journal.pone.0168618.g001
Table 2. Hazard ratios of participants hospitalized with infectious gastroenteritis among current Proton Pump Inhibitor (PPI) users compared to
non-users according to dose and type of PPI.
Characteristics HR* (95%CI) Ptrend Participants with chronic bowel
problems
Participants without chronic bowel
problems
Rate# HR** (95%CI) Ptrend Rate# HR** (95%CI) Ptrend
Average daily dose (DDD) <0.001 <0.001 <0.001
Non-users 1.0 22.1 1.0 9.4 1.0
0.5 1.1 (0.9–1.3) 25.2 1.2 (0.8–1.9) 10.8 1.1 (0.9–1.3)
0.5–1 1.4 (1.3–1.6) 37.5 1.7 (1.2–2.2) 14.3 1.4 (1.3–1.6)
>1 1.6 (1.3–1.8) 45.1 2.0 (1.4–2.8) 15.9 1.5 (1.3–1.8)
Type of PPI 0.2 0.3 0.4
Omeprazole 1.0 36.7 1.0 14.9 1.0
Pantoprazole 0.9 (0.8–1.1) 38.8 1.1 (0.7–1.6) 12.7 0.9 (0.7–1.1)
Lansoprazole 0.9 (0.6–1.2) 21.6 0.7 (0.3–1.7) 12.7 0.9 (0.6–1.2)
Rabeprazole 1.1 (0.9–1.3) 44.8 1.3 (0.8–2.0) 14.4 1.1 (0.8–1.3)
Esomeprazole 0.9 (0.8–1.1) 33.1 0.9 (0.6–1.4) 13.0 1.0 (0.8–1.1)
Rate# /1,000 person-years. HR* Adjusted for age, sex, region of residence, self-rated health, BMI, cancer in previous 5 years, history of chronic bowel
problems, H2 receptor antagonist use, recent antibiotic use, smoking and alcohol consumption. HR** Adjusted for age, sex, region of residence, self-rated
health, BMI, cancer in previous 5 years, recent H2 receptor antagonist use, recent antibiotic use, smoking and alcohol consumption.
doi:10.1371/journal.pone.0168618.t002
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(aHR: 2.0, 95% CI: 1.1–3.8). While not statistically significant in all cases, there was a pattern
of increased risk of these outcomes with increasing PPI dose, and this pattern was not gener-
ally observed for H2 receptor antagonists (Table 3).
Sensitivity Analyses
The results remained similar when restricting cases to only those with a principal hospital diag-
nosis of infectious gastroenteritis; compared to non-users, aHRs were 1.7 (95% CI: 1.4–1.9) for
current users and 1.5 (95% CI: 1.2–2.0) for former users. A significant dose-response relation-
ship was also observed; compared to non-users, aHRs were 1.1 (95% CI: 0.9–1.4), 1.4 (95% CI:
1.2–1.7) and 2.1 (95% CI: 1.8–2.5) in participants with a dose0.5, 0.5–1 and>1DDD/day,
respectively (Ptrend<0.001). In the second sensitivity analysis with PPI use as a time-varying
covariate, PPI use was also associated with infectious gastroenteritis hospitalization (aHR: 1.9,
95% CI: 1.6–2.1). Associations remained similar when further restricting the study population
to participants who did not change PPI use category during follow-up. A similar dose-response
relationship was retained in this analysis (Ptrend<0.001).
Discussion
In this study, we found a significantly increased risk of infectious gastroenteritis hospitaliza-
tion associated with PPI use, and a significant dose-response relationship among current







No. of events No. of events No. of events
PPI Non-users 30 21 43
PPI former users 3 5 7
PPI current users 51 45 97
Association between medication use and
infections
HR* (95%CI) HR* (95%CI) HR** (95%CI)
PPI use
Non-users 1.0 1.0 1.0
Former users 0.5 (0.2–1.6) 1.1 (0.4–2.9) 0.7 (0.3–1.6)
Current users 1.2 (0.7–1.8) 1.6 (1.0–2.7) 1.5 (1.1–2.1)
H2 receptor antagonist use
No 1.0 1.0 1.0
Yes 1.1 (0.3–3.3) 2.3 (0.9–5.9) 0.6 (0.2–1.7)
Antibiotic use
No 1.0 1.0 1.0
Yes 1.4 (0.9–2.3) 1.0 (0.6–1.6) 1.1 (0.8–1.5)
Average daily dose (DDD)
Non-users 1.0 1.0 1.0
Current users:0.5 0.8 (0.3–1.9) 1.4 (0.6–3.1) 1.2 (0.6–2.1)
Current users: 0.5–1 1.3 (0.8–2.1) 1.8 (1.1–3.0) 1.3 (0.9–2.0)
Current users: >1 2.0 (1.1–3.8) 1.1 (0.4–2.7) 2.2 (1.4–3.4)
HR* Adjusted for age, sex, region of residence, self-rated health, recent H2 receptor antagonist use, recent antibiotic use, cancer in previous 5 years,
history of chronic bowel problems, and alcohol consumption. BMI and smoking status were not included in the model due to missing values in certain
categories. HR** Adjusted for age, sex, region of residence, self-rated health, BMI, recent H2 receptor antagonist use, recent antibiotic use, cancer in
previous 5 years, history of chronic bowel problems, smoking and alcohol consumption.
doi:10.1371/journal.pone.0168618.t003
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users. This risk was specific to PPI users, as use of H2 receptor antagonists, which are used for
the same indication as PPIs, was not associated with hospitalization due to infectious gastroen-
teritis. This study confirms that the risk of infectious gastroenteritis hospitalization is elevated
in people who have used PPIs, and also provides new and reliable information about the effects
of different types of PPIs and dosages.
We found that former and current PPI users had significantly increased risks of infectious
gastroenteritis hospitalization compared to those never using or using PPIs12 months prior
to baseline. Previous studies have reported current PPI therapy as a significant risk factor for
bacterial gastroenteritis [18, 28]. Howell et al reported increasing rates of nosocomial C. diffi-
cile infection with increasing level of PPI therapy [29]. In this study, we observed a significant
dose-response relationship between PPI exposure and all-cause infectious gastroenteritis hos-
pitalization, which has not been demonstrated previously. This dose-response relationship,
and the fact that it is specific to PPIs and was not seen in users of H2 receptor antagonists, sup-
ports a causal association. In this study, we found a small elevation in risk of gastroenteritis
hospitalization among former users, which has not been investigated previously; it may be due
to long-term effects of PPI use, but requires confirmation.
The reason for the association between PPI use and infectious gastroenteritis is not known
definitively, although colonization and proliferation of pathogens secondary to acid suppres-
sive treatment is one potential explanation. Gastric acid plays an important role in preventing
human gastrointestinal infections [30] and an acidic environment in the upper gastrointestinal
tract constitutes one of the major non-specific defenses to protect against ingested microor-
ganisms [31]. Acid suppression induced by PPIs also affects gastrointestinal motility and can
indirectly alter gut microbiota [32]. In patients with functional bowel disorders, such as irrita-
ble bowel syndrome, such changes could be more pronounced [33, 34]. Our study found that
PPI use resulted in elevated risk of infectious gastroenteritis hospitalization in people with and
without a history of chronic bowel problems. We also observed higher rates of infectious gas-
troenteritis hospitalization and greater PPI use among participants with a history of chronic
bowel problems, indicating greater absolute risks of PPI-attributable hospitalization in this
group. This suggests that the necessity for PPI use may need to be evaluated more carefully in
this group of patients.
Previous studies have reported associations between PPI use and enteric infections, such as
Campylobacter, Salmonella [18] and C. difficile infection [35]. We found a broad association
between PPI use and Campylobacter-, Salmonella- and C. difficile infection. While the associa-
tion was not statistically significant in all cases, which could be due to smaller number of
events, there was a pattern of increased risk of infections in PPI users and potential dose-
response relationships. In addition, our prior work using the full 45 and Up Study dataset
showed a significant risk of Salmonella infection among people who self-reported PPI use at
baseline (aHR 1.87, 95%CI 1.43–2.40) [36]. Our findings regarding C. difficile infection were
consistent with published data. A recent systematic review of 39 studies showed PPI users at
higher risk of C. difficile infection compared to non-users (odds ratio: 1.74, 95%CI 1.47–2.85)
[9]. Based on latest evidence, the FDA have published safety alerts warning of the association
between C. difficile diarrhea and PPIs [37]. In Europe, PPI use for more than 8 weeks at the
maximal dose without clear indication has been listed on the European list (EU [7)-PIM list)
of potentially inappropriate medications for older people due to the association between PPI
use and C. difficile infection [38].
To ensure that the study focused on the likely causal effect of PPI use on infectious gastro-
enteritis hospitalization, comorbidity status was controlled through adjustments of cancer his-
tory, general health and BMI. Participants with digestive disorders may be more likely to be
prescribed acid suppressive medications. These patients also may be more likely to experience
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infectious gastroenteritis and be hospitalized. It was not possible to account for all possible
digestive disorders, although we identified participants with chronic bowel problems at base-
line and adjusted for them in the regression models. We also stratified results by the status of
chronic bowel problems. To examine the effect of confounding by indication of acid suppres-
sive therapy, we considered recent H2 receptor antagonist use in the analysis. Similar to PPIs,
H2 antagonists are a class of acid suppressants used to treat acid-related disorders such as pep-
tic ulcers. We did not observe any increased risk of infection among H2 receptor antagonist
users, indicating that confounding by indication was unlikely to be a major source of bias in
this study.
The large number of cases in the study enhanced the precision of the estimates, and allowed
adequate assessment of the effects of potential confounders. However, we were only able to
classify based on medication usage from dispensing data rather than directly observed therapy,
meaning we were unable to confirm actual PPI use in this study. Misclassification relating to
non-use among those with records of having been dispensed PPIs would tend to lead to an
overestimation of the potential risk of PPIs. However, this bias would be unlikely to affect the
assessment of dose, as it is less likely that patients with multiple dispensing records of PPIs did
not take the medication. In addition, a recent systematic review suggested that the majority of
patients with GERD are relatively adherent to PPIs, and adherence increases with severe symp-
toms [39]. Secondly, as with most observational studies, residual confounding by unmeasured
factors is a potential concern. In this study, we controlled for several important confounders,
although we were unable to assess other factors, such as use of over-the-counter antacids. Dur-
ing the study period, low-dose PPIs were available from pharmacies without a prescription in
Australia, which could lead to misclassification of PPI exposure. Thirdly, inpatient hospitaliza-
tion data can be subject to misclassification. However, sensitivity analysis restricting cases only
to principal diagnosis of infectious gastroenteritis showed similar results to the main findings.
Finally, the study population was restricted to concession-card-holders. Therefore, partici-
pants were likely to be older, with lower socio-economic status, when compared to the broader
cohort, although risk factor estimates are considered broadly generalizable from within-cohort
comparisons [40].
In summary, PPI use is associated with an increased risk of infectious gastroenteritis hospi-
talization in the 45 and Up Study participants, with higher risks with increasing doses. Given
the widespread use of PPIs, particularly among the elderly, clinicians should be aware of this
risk when considering PPI therapy, and use the lowest effective dose for patients with appro-
priate indications. For patients with chronic bowel problems, it may be worth considering an
alternative dosage or switching to H2 receptor antagonists.
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Abstract
Purpose of Review Noroviruses are the most common cause
of gastroenteritis outbreaks in long-term care facility (LTCFs).
This review summarizes the most up-to-date knowledge on
norovirus infection in LTCFs with the aim of identifying po-
tential strategies for management.
Recent Findings LTCF residents are at greater risk of
norovirus infection. Early identification of norovirus infection
and prompt initiation of appropriate supportive therapy are
required to reduce morbidity and mortality. Measures to pre-
vent outbreaks and reduce the risk of norovirus infection in
LTCFs include timely diagnosis and implementation of infec-
tion control interventions to limit virus transmission.
Summary Current guidelines for prevention and control are
based on generic principles of infection control. Real-time
reverse transcription-quantitative polymerase chain reaction
assays have been the gold standard for the rapid and sensitive
detection of noroviruses. With the recent breakthroughs of
human norovirus in vitro culture, doors are now opened to
evaluate the efficacy of environmental disinfectants and hand
hygiene options. Additionally, development of licensed vac-
cines against noroviruses may provide another important tool
for infection prevention among high-risk individuals.
Keywords Norovirus . Older adults . Long-term care
facilities . Management
Introduction
Human noroviruses are globally important pathogens, contrib-
uting substantially to the burden of acute gastroenteritis across
all age groups. The World Health Organization recently esti-
mated that noroviruses caused 684 million illnesses and over
200,000 deaths globally in 2010 [1••]. Ahmed et al. conducted
a systematic review of the scientific literature published from
January 1, 2008, toMarch 8, 2014, and found that noroviruses
were associated with almost one fifth of all cases of acute
gastroenteritis, and the prevalence was higher in high income
countries compared to low- and middle-income countries
[2••].
Long-term care facilities (LTCFs) are common settings for
outbreaks of norovirus infection, where they are responsible
for 30–80% of acute gastroenteritis outbreaks [3, 4, 5, 6•].
While noroviruses can cause both sporadic infections and out-
breaks in all age groups, older people are at higher risks of
hospitalization and death [3], owing to intrinsic factors, such
as age-related immunosenescence or the presence of comorbid
conditions, which result in more extended symptoms [7].
Additionally, elderly residents of LTCFs are at elevated risks
of infection as a result of institutionalized confinement that
promotes transmission by sharing rooms and touching com-
mon surfaces [8]. This review summarizes the most up-to-date
knowledge on norovirus infection in LTCF residents with the
aim of identifying potential strategies for management.
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Infection in Older Adults and in LTCFs
Norovirus infection generally manifests as a relatively brief,
self-limited illness in healthy immunocompetent individuals,
although it can cause significant morbidity and mortality in
frail elderly adults. Lindasay et al. reviewed 39 studies on risk
estimates of norovirus infection and found a high burden of
the infection in all ages with the highest rates of hospitaliza-
tion and death among the elderly [3]. Older people are at
higher risk of norovirus-associated hospitalization, resulting
in excess hospital stays and greater costs compared to young
adults [3]. The overall estimates of disease burden suggest that
noroviruses are responsible for approximately 10–20% of gas-
troenteritis hospitalizations, 10–15% of gastroenteritis deaths,
and ≥0.2% of all-cause mortality among older adults in upper-
middle-income and high-income countries [9, 10, 11•, 12, 13].
Additional data also suggest that noroviruses may trigger se-
vere clinical complications, including acute renal failure, ar-
rhythmia, chronic diarrhea, and severe enteropathy [14, 15].
Noroviruses are the most common cause of gastroenteritis
outbreaks in LTCFs [16]. Review of US outbreak surveillance
data show that over 60% of all norovirus outbreaks occur in
LTCFs [17], while in other high-income countries norovirus
outbreaks occur with roughly equal frequency in both acute-
care hospitals and LTCFs. The definition of LTCFs differs
between studies, but LTCFs generally refer to facilities that
provide prolonged care for individuals who required daily
living and/or nursing care support. Whereas most community
cases of norovirus are self-limiting within 12–60 h, outbreaks
of norovirus can significantly impact the institutionalized el-
derly and cause more severe or prolonged illness [18•, 19, 20].
Several factors contribute to the enhanced risk of severe
norovirus infection among older adults living in LTCFs, in-
cluding nutritional status, immunodeficiency or senescence,
chronic inflammation, microbiome alterations, and the use of
certain medications [21]. Decreased ability to maintain ade-
quate personal hygiene may also increase individual risk
among LTCF residents. Environmental factors, such as resi-
dence in close, shared quarters, use of shared facilities, and
limited ability to isolate infected residents, may contribute to
virus transmission in LTCFs. Shared dining facilities may also
increase risk for foodborne exposures.
Infection Transmission
Transmission of human noroviruses can occur directly
through person-to-person contact, or indirectly through con-
sumption of contaminated food or water, or through contact
with contaminated environmental surfaces (Fig. 1). Person-to-
person transmission is responsible for >90% of the norovirus
outbreaks in healthcare settings, where close living arrange-
ments, shared facilities and contact with visitors and staff
increase the risk of norovirus spread from one person to an-
other [17, 22]. Foodborne transmission is another important
route for the spread of noroviruses [1••] and can occur when
food handlers contaminate food on site or during the earlier
steps of food production [23]. An analysis of surveillance data
on norovirus outbreaks in the USA, Europe, and New Zealand
estimated that about 14% of norovirus outbreaks were attrib-
uted to foodborne transmission [24]. Noroviruses can also be
transmitted through contaminated environment surfaces and
aerosolized particles. Aerosolization of norovirus via vom-
itus can be particularly problematic in LTCFs, as virus
particles can settle on surfaces and survive for long
periods of time, leading to environmental contamination
for future exposure [25].
The high shedding titers in feces and vomit [26], low level
of infectious dose [27], and environmental stability [28] en-
able the virus to efficiently transmit via multiple modes.
Transmission has also been reported to occur before the onset
of symptoms [29], in the postsymptomatic period, and during
subclinical infections [30]. Investigations of norovirus out-
breaks in LTCFs confirmed that infected persons can asymp-
tomatically shed virus at high levels for at least 3 weeks [31••],
although reports from nosocomial norovirus outbreaks have
shown that symptomatic patients contribute primarily to trans-
mission of infection [32].
Importance of Genetic Diversity and Evolution
Noroviruses, divided into at least six genogroups (GI–GVI)
and more than 40 different genotypes (e.g., GII.4), are a ge-
netically diverse group of non-enveloped single-stranded
positive-sense RNA viruses [33]. The prevalence of infecting
genogroups and genotypes differ between populations and
route of transmission [22]. Genogroup I viruses are generally
associated with foodborne or waterborne outbreaks [24, 34],
while GII.4 viruses are strongly associated with person-to-
person transmission and occur predominantly in healthcare
and institutional settings [5, 6•, 35, 36]. Infections with
GII.4 viruses are more likely to cause severe infections, lead-
ing to more hospitalization and deaths than those caused by
other GII or GI viruses [37]. Multiple strains of noroviruses
can cause human reinfection. Protective immunity to specific
types of noroviruses has been reported, but with a limited
duration [38].
Despite the extensive genetic diversity, previous data sug-
gest that GII.4 viruses are responsible for the majority of
norovirus outbreaks worldwide [39], with a new GII.4 variant
strain emerging every 2–4 years [40]. Several mechanisms
may enhance GII.4 evolution, including the host herd immu-
nity that drives antigenic drift in the hypervariable P2 domain
[41••]. This domain of the viral capsid binds with human
histo-blood group antigens (HBGAs), which serve as a point
Curr Geri Rep
for initial viral attachment [42]. GII.4 viruses can bind a wider
range of HBGAs than other genotypes, causing infections to a
larger susceptible population [33]. Another explanation for the
emergence of novel GII.4 variants is related to homologous
recombination, which contributes to the emergence of the re-
cent pandemic GII.4 variants, such as GII.4 New Orleans
2009, and GII.4 Sydney 2012 [43]. The emergence of epidem-
ic strains of noroviruses has contributed to the changing epi-
demiology of norovirus infection worldwide [44, 45].
Clinical Features and Diagnosis
Noroviruses are highly contagious. Ingestion of a small num-
ber of viral particles can lead to infection [27]. The onset of
norovirus infection occurs after an average incubation period
of 1.2 (range 1–2) days [46]. Vomiting is a cardinal sign of
norovirus infection, along with acute onset of other gastroin-
testinal symptoms including nausea, watery and non-bloody
diarrhea, and abdominal cramps. Symptoms often last for 24–
72 h with complete recovery in immunocompetent individuals
[19], although older frail people may present with prolonged
symptoms and develop complications. One study describing
the clinical characteristics of nosocomial outbreaks found that
elderly hospitalized patients had prolonged symptoms with
norovirus infection, and almost one third of the patients expe-
rienced dehydration [47]. Notably, the majority of those study
participants (83.9%) had underlying chronic conditions, sug-
gesting that the impact of norovirus infection is more pro-
nounced among older adults with comorbid conditions.
It is difficult to diagnose norovirus gastroenteritis in indi-
vidual patients on the basis of clinical features alone. The
definition for norovirus infection in LTCFs requires the pres-
ence of both a compatible clinical presentation and a labora-
tory confirmation [48]. Historically, human noroviruses could
not be cultured in vitro. However, Jones et al. recently
published a protocol describing methods for culturing the
GII.4-Sydney human norovirus strain directly in human B
lymphocytes [49••]. This is a breakthrough research, as for
the first time, a human norovirus can be grown in a culture
dish. It enables research into the development of antiviral
drugs, as well as opens a door to definitively evaluate the
efficacy of infection control and prevention options.
Diagnostic methods of norovirus infection have focused on
detecting viral RNA or antigen. In recent years, real-time re-
verse transcription-quantitative polymerase chain reaction
(RT-qPCR) assays have become the gold standard for the rap-
id and sensitive detection of noroviruses in stool, vomitus,
foods, water, and environmental specimens [33]. However,
virus detection by RT-qPCR does not always correlate with
the disease. Infected persons can shed virus for weeks after
recovery from clinical symptoms, and noroviruses are also
frequently detected in stool samples from asymptomatic pa-
tients. Chan et al. analyzed data collected from sporadic cases
and speculated a correlation between viral load and virus
transmission from infected persons to susceptible hosts
through fecal-oral route [50]. This finding indicates that as-
sessment of a possible difference in viral load in samples may
be a useful tool to aid clinical interpretation and to assess
causal relationship.
Given the rapid spread of noroviruses, especially during
outbreaks, timely diagnosis is essential to assist management
and implementation of appropriate control measures. Rapid
commercial assays, such as enzyme immunoassays (EIAs)
have been cleared by the US Food and Drug Administration
to detect norovirus antigen in stool samples during outbreaks.
However, due to the poor sensitivity of EIAs [51], samples
with negative results should be confirmed by a second tech-
nique, such as RT-qPCR [52]. Consequently, EIA kits should
not replace molecular methods during outbreak investigations,
and caution should be used when interpreting test results from
sporadic cases [52].
Fig. 1 Norovirus transmission in
long-term care facilities
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In the absence of laboratory diagnostic tests or delays in
obtaining laboratory results, outbreaks of norovirus infection
can be identified according to Kaplan criteria [53]. These
criteria are based on the clinical and epidemiological profile
of illness, which include (1) vomiting in >50% of patients, (2)
a mean incubation period of 24–48 h, (3) a mean duration of
illness of 12–60 h, and (4) lack of bacterial pathogens in stool
culture. The set of Kaplan criteria is highly specific (99%),
although with moderate sensitivity (68%) in discriminating
outbreaks due to bacteria from those due to norovirus [54].
In LTCF, outbreaks satisfying Kaplan’s criteria may justify
rapid institution of control measures to limit spread of
infection.
Treatment
Currently, there is no specific antiviral therapy available to
treat norovirus infection. The management of patients is pri-
marily supportive and focuses on treatment of dehydration
and infection control measures to prevent further spread.
Dehydration is the most common complication that requires
medical care and is especially of concern among LTCF resi-
dents with underlying chronic conditions [55]. Patients with
comorbidities are often prescribedmultiple medications, some
of which may have a potential for drug interactions.
Therefore, the effect of fluid and electrolyte disturbance on
medications should be closely monitored among elderly
patients.
Despite recent progress in the development of norovirus
vaccines, licensed products are not yet available. Clinical trials
have demonstrated safety, immunogenicity, and efficacy of
some products [56, 57], although the development of
norovirus vaccines is challenging due to the high degree of
virus genetic diversity, rapidly evolving new variant strains,
and an incomplete understanding of immune correlates of
protection [41••, 58••]. The future efficacy of norovirus vac-
cines may rely on the development of products eliciting a
broad cross-protective immune response against heterologous
virus [41••]. It is clear that older adults living in LTCFs are at
higher risks of norovirus infection and are more likely to have
worse outcomes. Therefore, vaccinating LTCFs residents
would be beneficial to directly prevent infection transmission
and reduce disease burden [59•].
Prevention and Control of Norovirus Outbreaks
in LTCFs
The highly infectious nature of noroviruses and their environ-
mental persistence pose multiple challenges to infection man-
agement in LTCFs. In 2011, the Centers for Disease Control
and Prevent ion publ i shed gu ide l ines prov id ing
recommendations for the prevention and control of norovirus
gastroenteritis outbreaks in healthcare facilities [60]. Table 1
summarizes the risk-based approach for norovirus infection
prevention and management in LTCFs, based on these guide-
lines and other published recommendations [52, 60, 62, 63,
73•]. The major strategies have included measures for timely
diagnosis and implementation of infection control interven-
tions to limit virus transmission.
Cohorting and Exclusion
Social distancing measures, such as isolation or cohorting of
symptomatic patients, have been successful in limiting
norovirus transmission in large outbreaks [61]; however, the
appropriate duration of isolation and use of contact precau-
tions are uncertain. Patients may continue to shed norovirus in
Table 1 Measures recommended to manage norovirus infection in
long-term care facilities
Surveillance and diagnosis
• Surveillance for infectious gastroenteritis
• Access to laboratory facilities capable of timely and accurate
diagnosis of infection;
• Rapid testing of stool specimens for norovirus
• Outbreak notifications to appropriate health departments if norovirus
gastroenteritis is suspected
Disease control and prevention practices
Interruption of person-to-person transmission
• Isolation and cohorting of infected persons, if feasible
• Minimizing resident transfers
• Adherence to personal protective equipment use for persons
entering the patient care areas or caring for ill residents
• Hand hygiene with soap and water after contact with infected
residents, their body substances, or potentially contaminated
environment
• Informing visitors and residents about importance of hand hygiene
to prevent infection spread
• Training staff about the transmission, clinical features, diagnosis,
management, and prevention of norovirus infection
• Minimizing staff working at multiple facilities
• Ill staff exclusion until ≥48 h after symptoms resolve
Interruption of transmission via contaminated environment
• Disinfection and clean areas of any organic material
• Disinfection and sterilization using EPA approved products
• Restriction of staff working in contaminated areas
• Increasing the frequency of cleaning and disinfection of patient
care areas and frequently touched surfaces during outbreaks
Interruption of transmission via contaminated food and water
• Avoiding bare-hand contact with ready-to-eat foods and
appropriately hand hygiene practice before preparing foods
• Washing fresh foods and cooking shellfish thoroughly
• Enhancing cleaning in food facilities and contaminated areas
• Exclusion of ill food handlers until ≥48 h after symptoms resolve
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their stool after resolution of symptoms, and recommenda-
tions have beenmade tominimize contact with patients during
the acute phase of illness, and 24–72 h following recovery
while patients still shed virus at high levels [52]. This is par-
ticularly important during outbreaks in LTCFs to help break
the transmission cycle, prevent the amount of secondary trans-
mission, and also decrease the outbreak duration. Most guide-
lines recommend cohorting patients into groups according to
symptomatic, exposed asymptomatic, and unexposed asymp-
tomatic status, with dedicated healthcare staff providing care
for infected patients [52, 62, 63]. To minimize the risk of
transmission from incubating or asymptomatic cases, such
patients should not be transferred to unaffected areas, typically
within 48 h after exposure [52].
Environmental Disinfection
Noroviruses are stable and persistent in the environment [64].
Current evidence suggests that environmental contamination
with norovirus is common both within and outside outbreak
settings [28]. Therefore, environmental cleaning and chemical
disinfection are essential to interrupt the chain of virus trans-
mission. To maximize penetration and efficacy, initial
cleaning to remove gross organic matter should precede chem-
ical disinfection. CDC recommends sodium hypochlorite at
concentration of ≥1000 ppm for disinfection of hard and non-
porous environmental surfaces if feasible [52, 65]. The US
Environmental Protection Agency (EPA) has published a list of




Hand hygiene is another key part of interrupting the norovirus
transmission cycle, including environmentally mediated trans-
mission as contaminated hands can transfer virus to touched
surfaces, or vice versa [66]. Actively promoting adherence to
hand hygiene among staff and residents is strongly recom-
mended and should be implemented [52]. Handwashing with
soap and water have been reported as preferred means to pre-
vent infection, especially during an outbreak or if there is
gross fecal soiling of the hands [8, 52]. The efficacy of
alcohol-based sanitizers against noroviruses remains contro-
versial, and further research is required to evaluate the efficacy
of alcohol-based hand sanitizers against the virus [67, 68]. As
an additional preventive strategy during outbreaks, use of
gloves is recommended.
Staff Members
Staff of LTCFs plays an important role in infection transmis-
sion. A recent meta-analysis summarizing risk factors of
norovirus spread in nursing homes found a positive associa-
tion between bedside care and the infection [69]. Training staff
on the relevant guidelines and personal hygiene practices is
important to prevent transmission in LTCFs. Exposure to
vomit is another infectious risk [69]. Use of personal protec-
tive equipment, including gowns and facial masks, is recom-
mended for staff entering the patient care area or caring for
patients with gastroenteritis symptoms to reduce the likeli-
hood of exposure [60]. Ill staff members should not return to
work until ≥48 h after symptoms resolve [52, 70]. During
outbreaks of norovirus, staff working in multiple facilities
may facilitate spread of infection to other LTCF.
Food Safety
While food may become contaminated during production,
most norovirus contamination occurs during preparation
[71•]. Bare-hand contact by contagious workers with ready-
to-eat foods has been frequently identified in the majority of
reported foodborne norovirus outbreaks [71•]. Highly infec-
tious noroviruses may be transmitted through contaminated
food by ill catering or food service staff in LTCFs.
Therefore, food handlers are recommended to adherence to
appropriate recommendations for hand washing and avoiding
bare-hand contact with ready-to-eat foods (e.g., through use of
gloves or utensils). Ill food handlers should not return to work
until ≥48 h after symptom resolve [71•]. For asymptomatic
food service staff who have tested positive for norovirus, ex-
clusion is recommended [52]. CDC also recommends wash-
ing fresh product and thoroughly cooking shellfish as addi-
tional specific measures for preventing foodborne norovirus
transmission (http://www.cdc.gov/norovirus/preventing-
infection.html).
Surveillance and Outbreak Management
Surveillance for norovirus infection is recommended in
LTCFs to determine infection rates and outbreaks using the
standard case definition [48]. Outbreaks of norovirus infection
should be reported to health departments in accordance with
local regulations. Outbreak management is a multistage pro-
cess, including preparedness, identification, response, and
evaluation [72]. Guidelines for managing norovirus outbreaks
have been published by public health agencies in several high-
income countries [60, 62, 63]. Generally, LTCFs should de-
velop outbreak plans outlining management arrangements for
outbreaks, which may require involvement of public health
agencies. A facility outbreak control team, including physi-
cians, nurses, facility managers, and domestic staff should aim
to minimize the early spread of infection. The main ap-
proaches to infection control and prevention include
implementing policies concerning hand hygiene, patient iso-
lation and cohorting, ill staff exclusion from work, visitor
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restrictions, food safety, and environmental cleaning and dis-
infection [52, 60, 62, 63, 73•]. Early detection and isolation of
sporadic cases are also recommended to reduce the impact of
noroviruses introduced into LTCFs [69].
Conclusions
The key means of managing norovirus infection in LTCFs are
well-functioning infection control programs. Current guide-
lines for prevention and control are generally based on infec-
tion control principles, although the efficacy of those control
measures is poorly quantified due to the inability to culture the
virus. With the recent breakthroughs of human norovirus
in vitro culture, doors are now opened to, for example, defin-
itively evaluate the efficacy of environmental disinfectants
and hand hygiene options. In addition, there is no specific
antiviral therapy available to treat norovirus infection.
Therefore, development of licensed vaccines against
noroviruses may provide another important tool for infection
prevention among high-risk individuals.
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Salmonella Infection in Middle-Aged and Older Adults:
Incidence and Risk Factors from the 45 and Up Study
Yingxi Chen,1 Kathryn Glass,1 Bette Liu,2 Kirsty Hope,3 and Martyn Kirk1
Abstract
Background: Salmonella infection is one of the most common foodborne bacterial pathogens, and causes a
significant health burden globally. We investigated the incidence and risk factors for notification and hospi-
talization due to Salmonella infection in older adults.
Materials and Methods: We used the 45 and Up Study, a large-scale Australian prospective study of adults
aged ‡45 years, with record linkage to multiple databases for the years 2006–2012 to estimate the incidence of
notification and hospitalization for Salmonella infection and estimate hazard ratios using Cox regression.
Results: Over a total follow-up of 1,120,242 person-years, 333 adults had laboratory-confirmed Salmonella
infection and 101 were hospitalized; the notification and hospitalization incidence were 29.7 (95% confidence
interval [CI]: 26.9–33.3) and 9.0 (95% CI: 7.4–10.9) per 100,000 person-years, respectively. The risk of
Salmonella infection notification did not differ by age, but risk of hospitalization increased with age. Elderly
males had the highest risk of infection-related hospitalization. The risk of notification was higher for those
living in rural or remote areas (adjusted hazard ratio [aHR] 1.7, 95% CI 1.3–2.2), those taking proton pump
inhibitors (aHR 1.9, 95% CI 1.4–2.4), and those reporting chicken/poultry intake at least seven times per week
(aHR 3.2, 95% CI 1.3–7.9).
Conclusions: Chicken consumption remains a significant risk factor for Salmonella infection, highlighting the
importance of reducing contamination of poultry and improving food safety advice for older people.
Keywords: Salmonella infection, hospitalization, older adults
Introduction
Salmonella infection is a globally important cause offoodborne disease, causing an estimated 153 million
cases and 56 thousand deaths globally in 2010 (Kirk et al.,
2015). Salmonella spp. are widely distributed in domestic and
wild animals (World Health Organization, 2013) and most
infections are transmitted through contaminated food of
animal origin (Pires et al., 2014). Transmission through
contact with infected persons or animals and consumption
of contaminated water are less common in industrialized
countries (Sanchez-Vargas et al., 2011). Surveillance for
salmonellosis relies on molecular testing to identify
common-source outbreaks. In Australia, Salmonella Typhi-
murium is one of the most common serotypes, causing spo-
radic infections and foodborne outbreaks, of which the
majority are associated with the consumption of raw or un-
dercooked eggs (Moffatt et al., 2016).
The elderly are particularly vulnerable to Salmonella in-
fection, although few studies have specifically examined risk
factors for infection in this population. Salmonella infection
in older people can cause invasive disease, resulting in se-
vere complications (Parry et al., 2013) and higher mortality
(Scallan et al., 2015). In one study in Victoria, Australia,
examining Salmonella infection in people over 65 years old,
the case fatality rate of people infected with Salmonella
Typhimurium was 1.6%, compared to 1.2% for all other se-
rotypes (Kirk et al., 2012). In addition, the study found that
rates of salmonellosis in elderly people rose dramatically
over 2000–2009 (Kirk et al., 2012). The cause of the increase
in rates is unknown, although could be linked to consumption
of chicken meat and eggs which were identified as the
common source of outbreaks through surveillance (Ozfood-
net Working Group, 2015).
Understanding the epidemiology of Salmonella infec-
tion is important to guide interventions to reduce its health
burden, particularly among high-risk groups. In this study,
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we estimate the incidence and risk factors for laboratory-
confirmed Salmonella infection and hospitalization in a large
prospective study of adults aged 45 years and older in the
Australian state of New South Wales (NSW).
Materials and Methods
The Sax Institute’s 45 and Up Study is a prospective cohort
study of Australian adults aged 45 years and older, randomly
sampled from the general population of the Australian state
of NSW (population 6.8 million persons, 2006) (Australian
Bureau of Statistics, 2007) (45 and up Study Collaborators
et al., 2008). Eligible individuals received a mailed invitation
to participate, with an information leaflet, a consent form and
the study questionnaire. Participants were recruited by
completing the postal questionnaire between 2006 and 2008.
The final study cohort includes *10% of the whole popu-
lation aged 45 years and older in NSW.
Self-reported data from the 45 and Up Study participants
were linked to the NSW Notifiable Conditions Information
Management System (NCIMS) (to June 30, 2012), the NSW
Admitted Patient Data Collection (APDC) (to June 30, 2012),
and the NSW Register of Births, Deaths and Marriages
(RBDM) (to June 30, 2012). In NSW, health practitioners and
laboratories are required to report confirmed Salmonella in-
fection under the Public Health Act 2010 (NSW Ministry of
Health, 2010). Salmonella infection is confirmed based on
isolation or detection of non-typhoidal Salmonella (NTS)
species, and only confirmed cases are entered into NCIMS
(Department of Health).
The NCIMS database contains a record of all Salmonella
infection notifications in NSW, including the estimated onset
date, the type of laboratory specimen used for confirmation,
and the serotype of Salmonella. The APDC records details of
all hospital separations for NSW residents admitted to hos-
pitals, the principal diagnosis responsible for the admission
coded using the International Classification of Diseases
10th revision-Australian Modification (ICD-10-AM) and
up to 54 additional diagnoses contributing to the hospitali-
zation. The RBDM database provides information on all
deaths in NSW and the date of death.
The Centre for Health Record Linkage conducted the data
linkage independently using identifiers such as name and date
of birth in each of the records. Audits demonstrated false
positive and false negative linkage rates of respectively
<0.5% and <0.1% (Centre for Health Record Linkage).
Case definitions
We defined participants as having a Salmonella infection
notification if they had a linked NCIMS record of NTS in-
fection and categorized them into two groups: Salmonella
Typhimurium and all other Salmonella serotypes (other
Salmonella serotypes). We defined participants as having a
Salmonella-related hospitalization if they had a linked
NCIMS record of a NTS infection and a hospital admission
date within a period of 1 week before and up to 4 weeks
following the date of the notification where the hospital di-
agnosis was coded with an ICD-10-AM code prefixed with
A02 (other Salmonella infections), or A09 (other gastroen-
teritis and colitis of infectious and unspecified origin).
Statistical analysis
Participants who had a linked notification record for Sal-
monella infection in the 30 days before recruitment to the 45
and Up Study were excluded from the analysis. To estimate
incidence of Salmonella infection notification, follow-up
time was calculated from the date of study entry to the 45 and
Up Study to the first notification of NTS infection, death, or
the last date which we had complete linked follow-up data
( June 30, 2012), whichever came first.
Incidence was calculated by age (45–54, 55–64, 65–74,
75–84, or ‡85 years), sex, annual household income (six
categories from less than $20,000 to $70,000 or more per
year), region of residence (cities, suburban, and rural/remote)
based on the Accessibility/Remoteness Index of Australia
(Department of Health, 2001), health status variables in-
cluding self-rated health (excellent, very good, good, fair,
poor) and body mass index (BMI: <18.5, 18.5–24.9, 25–29.9,
‡30 kg/m2). Salmonella-related hospitalization incidence
was estimated using the admission date for first hospitaliza-
tion with Salmonella infection.
In the analyses, missing values were categorized as miss-
ing for each variable. We then estimated the risk factors of
Salmonella infection notification according to various so-
ciodemographic and other characteristics that had either been
reported to be associated with Salmonella infection previ-
ously, or were associated with the notification incidence in
the cohort: age, sex, annual household income, region of
residence, self-rated health and BMI, frequency of seafood
consumption (None, <7 times/week, ‡7 times/week), fre-
quency of chicken/poultry consumption (None, <7 times/
week, ‡7 times/week), egg consumption (ever, never), fruit
and raw vegetable consumption (low, adequate), proton
pump inhibitor (PPI) use (yes, no), smoking (ever, never) and
alcohol consumption (none, 1–2 drinks/day, >2 drinks/day).
Continuous variables were grouped into categories and
treated as categorical. Firstly, Kaplan-Meier survival curves
were produced for all study variables. Cox proportional
hazards regressions were then used to calculate hazard ratios
(HR) for Salmonella infection notification. Regression
models were firstly adjusted for age and sex. Models were
then adjusted for additional variables that were associated
with the notification incidence in the cohort (log-rank test,
p < 0.3).
We reviewed all APDC records where a participant was
hospitalized with Salmonella infection to obtain data on co-
morbidities and characteristics of the hospitalization. We
again used Cox proportional hazards regression to examine
the HRs for Salmonella-related hospitalization, with the same
model-building strategy as for the risk factor analysis for
Salmonella infection notification.
We conducted supplementary analyses to calculate the
incidence and examine risk factors of infection notification
and hospitalization by Salmonella serotypes. Serotypes were
grouped as Salmonella Typhimurium and other Salmonella
serotypes, respectively. The proportionality assumptions for
the model were assessed graphically. All analyses were car-
ried out using STATA 12.1.
Ethics approval
The conduct of the 45 and Up Study was approved by the
University of New South Wales Human Research Ethics
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Committee. Ethics approval for this study was obtained from
the NSW Population and Health Services Research Ethics
Committee, and the Australian National University Human
Research Ethics Committee. All participants provided writ-
ten informed consent.
Result
Overall, 265,074 adults were included in the analyses,
yielding a total of 1,120,242 years of follow-up (median 3.9
years per person). The median age of study participants at
recruitment was 62.7 years (standard deviation 11.2) and
53.6% were women. There were 333 adults with a linked
notification of Salmonella infection during follow-up, with
45.4% (151/333) due to Salmonella Typhimurium.
Salmonella infection
The incidence of Salmonella infection notification in the
cohort was 29.7 per 100,000 person-years (95% confidence
interval [CI], 26.9–33.3) (Table 1).
Incidence did not differ by sex ( p= 0.9) or household in-
come ( p = 0.3), but did by age group ( p = 0.03) and region of
residence ( p = 0.002). After adjustment, region of residence,
PPI use and chicken/poultry intake remained significant risk
factors for Salmonella infection notification; see Table 2.
Participants reporting chicken/poultry intake at least seven
times per week had a significant risk of notification (adjusted
hazard ratio [aHR] 3.2, 95% CI 1.3–7.9). Participants living
in rural/remote areas were 70% more likely to have Salmo-
nella infection notification as those living in cities (aHR 1.7,
95% CI 1.3–2.2), while for those taking PPIs, the risk was 1.9
times higher than for those not taking PPI (aHR 1.9, 95% CI
1.4–2.4) (Table 2).
A total of 101 participants with Salmonella infection had a
hospitalization related to their condition. Of these, 76.2%
(77/101) had an ICD-10-AM diagnosis code on their hospi-
talization record indicating a Salmonella infection (A02), and
23.8% (24/101) had a hospitalization coded as infectious
gastroenteritis (A09) and an adjacent notification of Salmo-
nella infection. One participant died within 30 days of ad-
mission, and six participants died within 60 days of
admission. Participants aged ‡65 years old accounted for all
the deaths. The hospitalization incidence was found to in-
crease with increasing age (Ptrend <0.001), and in univariate
analysis, men were more likely to be hospitalized than wo-
men ( p = 0.02). After adjustment, men were 70%more likely
to be hospitalized with Salmonella infection (aHR 1.7, 95%
CI 1.1–2.6). Compared to participants living in cities, the risk
was significantly higher in participants from suburban areas
(aHR 1.6, 95% CI 1.1–2.6) and rural/remote areas (aHR 1.9,
95% CI 1.1–3.2) (Table 2).
Subgroup analysis
The incidence of infection notification with Salmonella
Typhimurium was 13.5 per 100,000 person-years (95% CI,
11.5–15.8), and for all other Salmonella serotypes was 16.2
per 100,000 person-years (95% CI, 14.1–18.8). The notifi-
cation incidence of each serotype within the population did
not differ by age and sex. The incidence of hospitalization
with Salmonella Typhimurium was 5.1 per 100,000 person-
years (95% CI, 3.9–6.6), and that of other Salmonella sero-
types was 3.9 per 100,000 person-years (95% CI: 2.9–5.2)
(Supplementary Table S1; Supplementary Data are available
online at www.liebertpub.com/fpd).
Overall results of the risk factor analysis for other Sal-
monella serotypes were generally similar to the results of the
main analysis, with region of residence, PPI use and chicken/
poultry intake remaining significant risk factors. While none
of the variables were significantly associated with notifica-
tion for Salmonella Typhimurium infection, the direction of
association was consistent with the main findings (Supple-
mentary Table S2).
Discussion
We found that approximately one-third of the participants
with Salmonella infection notification were hospitalized.
This proportion increased with age, and was particularly high
Table 1. Incidence of Salmonella Infection Notification and Infection-Related











person years n/N (%)
Age (years)
45–54 93 28.0 (22.8–34.3) 20 6.0 (3.9–9.3) 21.5
55–64 104 28.5 (23.5–34.5) 27 7.4 (5.0–10.7) 26.0
65–74 62 25.4 (19.8–32.6) 21 8.6 (5.6–13.1) 33.9
75–84 63 42.3 (33.1–54.2) 25 16.7 (11.3–24.7) 39.7
+85 11 36.6 (20.2–66.0) 8 26.4 (13.2–52.8) 72.7
Sex
Female 178 29.6 (25.5–34.3) 43 7.1 (5.3–9.6) 24.2
Male 155 29.9 (25.5–35.0) 58 11.1 (8.6–14.4) 37.4
Total 333 29.7 (26.9–33.3) 101 9.0 (7.4–10.9) 30.3
aDiagnoses of other Salmonella infections (A02) and other gastrointestinal infections (A09).
CI, confidence interval.
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among those aged ‡85 years, where almost three-quarters
were admitted for their illness. While the incidence of
Salmonella infection notification was similar across age
groups, infection-related hospitalization increased signifi-
cantly with age. Importantly, older people consuming
poultry more than seven times per week were at the highest
risk of infection.
Our estimates are similar to the findings from a number of
industrialized countries. One US study using surveillance
data to determine the rates of hospitalization and death as-
sociated with laboratory-confirmed Salmonella infection re-
ported that people aged ‡60 years had the highest rate of
hospitalization, with 47% of infected persons hospitalized
(Kennedy et al., 2004). We used linked notification data in
our study and would expect our estimate of Salmonella in-
cidence to be similar to that for routinely collected surveil-
lance data. The incidence of the notification of Salmonella
infection among people aged ‡60 years in our study (31.5 per
100,000 person-years) was comparable with the reported
notification incidence in the same age group in NSW (36.4
per 100,000 person-years)—the state where the cohort study
was conducted (NSW Ozfoodnet, 2011).
We identified that males aged ‡85 years were at the highest
risk of hospitalization, despite having similar incidence of
infection notification to other cohort participants. This may
be because of an increased susceptibility of developing se-
vere complications from infection with aging (Cummings
et al., 2012) which may lead to hospitalization. Other factors,
such as sex differences in the incidence of invasive Salmo-
nella infection (Vugia et al., 2004) may explain the higher
risk of Salmonella-related hospitalization in males.
We found that people living in rural areas had an elevated
risk of Salmonella infection and hospitalization. In Australia,
the rate of poverty in regional and rural areas is higher than in
major cities. Ecological studies have reported higher rates of
Salmonella infection from low income areas (Varga et al.,
2013), which may be explained by poorer microbial quality
of food or greater exposure to high-risk foods (Koro et al.,
2010). One study reported that human contact with cattle
might pose higher risks than food consumption for bovine
strains of Salmonella (Hoelzer et al., 2011).
Environmental exposures related to rural living may be
important determinants of Salmonella infection. Additionally,
we found that people living in remote areas were more likely
to have infection notification from Salmonella serotypes other
than Typhimurium, which is consistent with the geographical
clustering of infection observed in notification data (Ashbolt
and Kirk, 2006).
Table 2. Association Between Sociodemographic and Health Characteristics













45–54 93 1 20 1
55–64 104 0.9 (0.7–1.2) 0.7 27 1.1 (0.6–1.9) 0.8
65–74 62 0.7 (0.5–1.1) 0.1 21 1.0 (0.5–1.9) 0.9
75–84 63 1.2 (0.8–1.7) 0.2 25 1.7 (0.9–3.2) 0.1
+85 11 1.0 (0.5–1.9) 0.8 8 2.8 (1.2–6.6) 0.02
Sex
Female 178 1 43 1
Male 155 1.0 (0.8–1.2) 0.7 58 1.7 (1.1–2.7) 0.01
Region of residence
Cities 121 1 34 1
Suburban 124 1.4 (1.0–1.7) 0.02 40 1.6 (1.1–2.6) 0.3
Rural/remote 88 1.7 (1.3–2.2) <0.001 27 1.9 (1.2–3.2) 0.1
Proton pump inhibitor usage
No 251 1 77 1
Yes 82 1.9 (1.4–2.4) <0.001 24 1.4 (0.9–2.3) 0.1
Chicken/poultry intake
None 8 1 4 1
<7/week 245 1.6 (0.8–3.2) 0.2 74 1.3 (0.5–3.8) 0.6
‡7/week 11 3.2 (1.3–7.9) 0.01 2 1.4 (0.3–8.1) 0.7
Self-rated health
Excellent 35 1 6 1
Very good 95 1.1 (0.7–1.6) 0.7 22 1.3 (0.5–3.2) 0.6
Good 126 1.5 (1.0–2.2) 0.04 42 2.2 (0.9–5.3) 0.08
Fair 55 1.8 (1.1–2.8) 0.01 18 2.3 (0.9–5.9) 0.1
Poor 11 2.1 (1.1–4.2) 0.04 7 4.5 (1.4–14.1) 0.01
aAdjusted for age, sex, household income, region of residence, living in aged care facilities, proton pump inhibitor usage, fruit and
vegetable intake, chicken/poultry intake, seafood intake, egg consumption, BMI, Self-rated health, smoking, alcohol consumption.
BMI, body mass index; CI, confidence interval.
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Participants with Salmonella Typhimurium infection were
more likely to be hospitalized than people with infection of
other Salmonella serotypes, and this was consistent across all
age groups. In participants aged ‡85, all cases with Salmo-
nella Typhimurium infection were hospitalized for their
condition, while only half of the cases with infection of other
Salmonella serotypes were admitted to hospital. Salmonella
serotypes are closely related genetically, and yet differ sig-
nificantly in pathogenicity. Further studies are needed to
investigate the pathophysiology of human Salmonella infection.
Understanding the mechanisms responsible for Salmonella
pathogenesis is important to understand invasiveness of
Salmonella infection, and thus prevent hospitalization.
Among all the food exposures analyzed in our study,
chicken/poultry consumption was significantly associated
with Salmonella infection; this was not true of Salmonella
Typhimurium but could be due to the smaller number of
events. A meta-analysis of case-control studies to investigate
source attribution of human salmonellosis identified con-
sumption of chicken in the restaurant as an important risk
factor for infection (Domingues et al., 2012). Sub-analyses of
the systematic review also showed a different risk profile for
infection by serotypes (Domingues et al., 2012). Similarly,
Glass et al. adopted a Bayesian source attribution model to
estimate the contribution of different animal reservoirs to
Salmonella infection and found that sources vary for different
serotypes, with eggs more commonly indicated for Salmo-
nella Typhimurium than non-Typhimurium serotypes (Glass
et al., 2016).
We did not observe any significant association between
egg consumption and Salmonella infection, but this may be
due to the fact that the baseline questionnaire used in this
study only asked participants if they ever eat eggs, and did not
collect information on frequency of egg consumption.
PPI use is another common risk factor for Salmonella in-
fection (Wu et al., 2014). In this study, we found that PPI use
was significantly associated with Salmonella infection. Al-
though we are not able to assess whether this increased risk is
owing to host factors that are associated with PPI prescription
(Brophy et al., 2013), or if the increasing risk is due to the use
of PPIs, our result adds to the body of evidence that PPI use is
associated with Salmonella infection.
The strengths of our study are: the large study population,
prospective independent ascertainment of notification and hos-
pitalization with Salmonella infection in relation to risk factors,
and the use of laboratory-confirmed cases. However, there were
some limitations to this study. First, the use of passive notifi-
cation data underestimates true incidence in the community
(Hall et al., 2008; Mytton et al., 2015). Moreover, notifications
which are mainly dependent on access to health services may
under-represent deprived populations. Such biases may lead to
an underestimation of incidence in those populations.
Second, data on exposures were based on self-report and
collected at the time of recruitment. Although dietary intake
is difficult to assess, a validation study involving the short
questions related to diet used in the 45 and Up Study ques-
tionnaire has shown them to be reproducible over time
(Roddam et al., 2005). Third, the 45 and Up study cohort,
while including about 1 in 10 adults in the age range in NSW,
may not be exactly representative of the general NSW pop-
ulation and participants are likely to bemore health conscious
than the general NSW population.
Despite this, we found that the incidence of Salmonella
infection from this study were generally comparable with the
reported notification incidence in the same age group in
NSW. Furthermore, risk factor estimates are still generaliz-
able from within-cohort comparisons (Mealing et al., 2010).
Conclusions
One-third of participants with laboratory-confirmed
Salmonella infection were hospitalized and the risk of hospi-
talization increased significantly with age. Understanding fac-
tors contributing to hospitalization in this group can assist
public health agencies in shaping effective risk reduction ef-
forts and effective care management. Previous data have sug-
gested Salmonella contamination of poultry meat (Fearnley
et al., 2011). Despite public health efforts to reduce food-
borne infections, chicken consumption remains a significant
risk factor for Salmonella infection, highlighting the impor-
tance of reducing contamination of poultry and ensuring ed-
ucation about safe cooking practices reach older people.
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SUMMARY
Clostridium difﬁcile is the principal cause of infectious diarrhoea in hospitalized patients. We
investigated the incidence and risk factors for hospitalization due to C. difﬁcile infection (CDI) in
older Australians. We linked data from a population-based prospective cohort study (the 45 and
Up Study) of 266 922 adults aged 545 years recruited in New South Wales, Australia to
hospitalization and death records for 2006–2012. We estimated the incidence of CDI
hospitalization and calculated days in hospital and costs per hospitalization. We also estimated
hazard ratios (HR) for CDI hospitalization using Cox regression with age as the underlying time
variable. Over a total follow-up of 1 126 708 person-years, 187 adults had an incident CDI
hospitalization. The crude incidence of CDI hospitalization was 16·6/100 000 person-years, with
a median hospital stay of 6 days, and a median cost of AUD 6102 per admission. Incidence
increased with age and year of follow-up, with a threefold increase for 2009–2012. After
adjustment, CDI hospitalization rates were signiﬁcantly lower in males than females (adjusted HR
0·6, 95% conﬁdence interval 0·4–0·7). CDI hospitalization rates increased signiﬁcantly over 2009–
2012. There is a need to better understand the increasing risk of CDI hospitalization in women.
Key words: Clostridium difﬁcile, epidemiology.
INTRODUCTION
Clostridium difﬁcile is the principal cause of infectious
diarrhoea in hospitalized patients [1]. The burden of
disease due to C. difﬁcile infection (CDI) has been in-
creasing in the past decade with marked increases in
severe cases and deaths related to CDI [2, 3]. A sys-
tematic review investigating the economic impact of
CDI found that attributable mean CDI costs per
admission ranged from AUD 8911 to AUD 30 049
for hospitalized patients globally [4]. A cross-sectional
study conducted in Sydney, Australia, reported that C.
difﬁcile was one of the most frequently detected patho-
gens in patients who visited public hospitals for
gastrointestinal illnesses, and that 69% of people
infected with C. difﬁcile were aged 550 years [5].
Australian national surveillance for hospital-identiﬁed
CDI has demonstrated increasing incidence since
2011, highlighting a need to further characterize the
epidemiology of these infections [6].
Environmental contamination and frequent antibi-
otic use are the most important determinants of
hospital-acquired CDI internationally [7]. In addition,
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advanced age is strongly associated with infection and
severe clinical presentation [8]. While C. difﬁcile is gen-
erally thought of as a hospital problem, data from indus-
trialized countries suggest that community-acquired
infections are on the rise and comprise about 27–41%
of all cases of CDI in such countries [8, 9]. Patients
with community-acquired CDI tend to be younger com-
pared to those infected in the hospital setting and they
often lack exposure to antibiotics [10], suggesting the ex-
istence of other important risk factors for infection.
Recently, C. difﬁcile has been isolated from various
foods such as red meat and minimally processed fruit
and vegetables [11, 12], although further studies are ne-
cessary to conﬁrm food as an infection source.
There have not been any previous population-based
cohort studies describing the epidemiology of CDI
hospitalization in Australia. The aim of this study
was to describe the epidemiology of hospital-identiﬁed
CDI in mid-age and older Australians. Speciﬁcally, we
analysed data from a large population-based longitu-
dinal cohort to estimate the incidence of CDI hospital-
ization, quantify its association with potential risk
factors, and calculate the median length of hospital
stay and in-hospital costs per admission with CDI.
METHODS
Data sources
The Sax Institute’s 45 and Up Study is a prospective
cohort study of Australian adults aged545 years, ran-
domly sampled from the general population of the
Australian state of New South Wales (NSW; popula-
tion 6·8 million persons, 2006) [13]. Participants were
recruited by completing a postal questionnaire, distrib-
uted from 2006 to 2009. The ﬁnal cohort includes
∼10% of all NSW adults aged545 years. The detailed
methodology is described elsewhere [14].
Questionnaire data from the 45 and Up Study par-
ticipants were linked to the NSW Admitted Patient
Data Collection (APDC) (to 30 June 2012), and the
NSW Register of Births, Deaths and Marriages
(RBDM) (to 30 June 2012). The APDC records
details of all hospital separations for NSW residents
admitted to hospitals. The principal diagnosis for
each hospitalization, which is the main reason for hos-
pitalization and up to 54 additional diagnoses contrib-
uting to the hospitalization, were coded using the
International Classiﬁcation of Diseases, 10th revision,
Australian Modiﬁcation (ICD-10-AM). These data
also included the Australian Reﬁned Diagnosis
Related Group (DRG) code for each hospitalization.
Each DRG represents a class of patients with similar
clinical conditions requiring similar hospital resources
[15]. Data were linked to the RBDM to ascertain fact
of death for censoring purposes. The NSW Centre for
Health Record Linkage performed the data linkage
independent of the study investigators and report
false-positive and false-negative linkages of < 0·5%
and <0·1%, respectively [16].
Case deﬁnition
We deﬁned participants as having a CDI hospitaliza-
tion if they had a linked hospitalization record where
the principal diagnosis ﬁeld was coded for C. difﬁcile
colitis (ICD-10-AM code A04·7) following recruit-
ment into the study. In a sensitivity analysis, we broa-
dened the case deﬁnition to include patients where
either the principal or a secondary diagnosis ﬁeld
was coded with C. difﬁcile colitis.
Deﬁnition of outcomes
The study outcomes included incident hospitalization
with CDI and, in those hospitalized with incident
CDI, days in hospital and costs per admission
(AUD). For transfer patients, the relevant admission
records were ﬁrst merged together. Days in hospital
per hospitalization was calculated by subtracting the
discharge date from the admission date, except for
same day admissions where the length of stay was
assigned to be a single day. To estimate C.
difﬁcile-associated hospital costs per hospitalization,
we used the DRG codes of the index hospitalization
due to CDI and assigned an average cost based on
DRG cost data from the National Hospital Cost
Data Collection Public Sector Estimated Cost
Weights Reports (NHCDC) [17]. The NHCDC docu-
ments average costs per DRG, based on patient-costed
and cost-modelled information. Average DRG-speciﬁc
total cost per admission in Round 14 (2009–10)
NHCDC was used (version 5.2 for admissions from
January 2006 to December 2009 and version 6.0x
from admissions from January 2010 to June 2012).
Deﬁnition of potential risk factors
Sociodemographic information was obtained from the
baseline questionnaire and included: age (grouped as
45–54, 55–64, 65–74, 75–84, 585years), sex, annual
household income (seven categories from <AUD
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20 000 to5AUD 70 000 per year), and region of resi-
dence (cities, inner regional, outer regional/remote)
based on the Accessibility/Remoteness Index of
Australia (ARIA) [18]. Health status and health-
behaviour variables included: self-rated health (excel-
lent, very good, good, fair, poor), body mass index
(BMI: <18·5, 18·5–24·9, 25–29·9, 530 kg/m2), smok-
ing (current, past, never), alcohol (0, 1–2, >2 alcohol
drinks per day), proton pump inhibitor (PPI) use
(yes, no), red meat intake (0, 1–7, 57 times per
week), and fruit and vegetable intake (low, adequate).
Fruit and vegetable intake was grouped as ‘low’ if par-
ticipants reported <2 servings of fruit and/or <5 ser-
vings of vegetables per day.
In addition, the Charlson comorbidity index was
used to describe comorbid illness of the participants
hospitalized with CDI. This index is a well-validated
measure of comorbidity burden, and has been mod-
iﬁed to produce reliable estimates using ICD-10
codes [19]. The 19 Charlson conditions were selected
and weighted according to their potential inﬂuence
on mortality (scores were categorized as 0, 1, 2, 3).
Baseline data from the 45 and Up Study participants
were also linked to the APDC retrospectively to ob-
tain hospitalization records before recruitment.
Statistical analysis
Participants were excluded from the analyses if they
had missing data on date of entry into the study, an
invalid death date or conﬁrmed linkage errors.
Participants with a discharge diagnosis of CDI within
8 weeks prior to recruitment were excluded to remove
recurrent cases.
Follow-up was calculated from the date of complet-
ing the baseline survey to the ﬁrst date of admission
for CDI, death, or 30 June 2012, whichever came
ﬁrst. The crude rate of incident CDI hospitalization
in the cohort, and median days in hospital and costs
per admission for those hospitalized for CDI, were
calculated. Rates were also reported separately by
quarter and calendar year (2009, 2010, 2011, 2012),
and by the various sociodemographic factors, health
characteristics and behaviors.
To identify the risk factors for CDI hospitalization,
Kaplan–Meier analysis with the log-rank test was ﬁrst
used to determine the probability of hospitalization
with CDI for all potential risk factor variables. Cox
proportional hazards regressions were then used to es-
timate hazard ratios for each of these variables with
age as the underlying time variable [20]. Regression
models were initially adjusted for attained age (the
underlying time variable) and sex. Models were then
adjusted for additional variables that were associated
with CDI hospitalization (log-rank test, P< 0·3), in-
cluding annual household income, region of residence,
health status variables (self-rated health and body
mass index), PPI use and dietary variables (red meat
intake and fruit and vegetable intake).
A sensitivity analysis was conducted by repeating
the analysis with the case deﬁnition modiﬁed to include
patients where either the principal or additional diag-
nosis ﬁeld was coded for CDI. We tested for violation
of the proportionality assumptions for the model by
inspecting the log-log plots. All analyses were per-
formed using Stata v. 12.1 (StataCorp., USA).
Ethical approval
The conduct of the 45 and Up Study was approved by
the University of New South Wales Human Research
Ethics Committee. Ethics approval for this study was
obtained from the NSW Population and Health
Services Research Ethics Committee, and the
Australian National University Human Research
Ethics Committee. All participants provided written
informed consent.
RESULTS
After excluding participants with invalid death
records (death before recruitment, n= 12), conﬁrmed
linkage errors (n= 192), and those with a CDI hospi-
talization in the 8 weeks prior to recruitment (n= 3),
there were 266 922 participants included in the ana-
lysis, yielding 1 126 708 years of follow-up (median
3·9 years per person). The median age of study parti-
cipants at recruitment was 61·1 years (range 45·0–
106·2 years), and 53·6% were women. Table 1 shows
a summary of the characteristics of all study partici-
pants and those hospitalized with CDI.
There were 187 participants with an incident CDI
hospitalization, and 5·4% (10/187) died within 30
days of admission. Overall, 25·1% (47/187) of cases
had a Charlson index of51, although this proportion
increased with increasing age (respectively, 9·1% and
47·6% in those aged 45–54 years and 585 years).
We found that 37·4% (70/187) of cases had a history
of hospitalization in the previous 2 weeks and 67·9%
(127/187) of cases had a hospital admission in the
previous 3 months.
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During follow-up, the incidence of CDI hospitaliza-
tion was 16·6/100 000 person-years [95% conﬁdence
interval (CI) 14·4–19·2], with a median of 6 days
[interquartile range (IQR) 4–10] spent in hospital per
admission, and a median hospital cost of AUD 6102
(IQR 1909–6182) per admission.
The crude incidence of CDI hospitalization
increased with age as: 6·6 (95% CI 4·3–9·9), 8·7
(95% CI 6·1–12·3), 19·9 (95% CI 15·1–26·4), 41·2
(95% CI 32·9–53·9) and 69·4 (95% CI 45·3–106·4)
per 100 000 person-years in those aged 45–54 years,
55–64 years, 65–74 years, 75–84 years and 585
years, respectively (P <0·001). Rates also increased
with year of follow-up, with a threefold increase
over the study period from 10·2/100 000 person-years
in 2009 to 32·0/100 000 person-years in 2012 (P <
0·001). Crude CDI hospitalization rates were higher
in females (P< 0·001), in those living in cities com-
pared to regional/remote regions (P = 0·002), in
those taking PPIs (P = 0·002), and in those with
poorer self-rated health (P < 0·001). Crude incidence
did not differ signiﬁcantly by BMI, smoking, alcohol,
or food consumption.
After adjustment for age and other factors (as listed
in Fig. 1), sex and self-rated health remained signiﬁ-
cant variables of CDI hospitalization. Males were
40% less likely to be hospitalized with CDI than
females [adjusted hazard ratios (aHR) 0·6, 95% CI
0·4–0·7], while the aHRs increased signiﬁcantly with
poorer self-reported health with risks over ﬁve times
greater for those with poor vs. those with excellent
health (aHR 5·7, 95% CI 2·1–15·5). No statistically
signiﬁcant associations between other exposures and
incident CDI hospitalization were observed.
Sensitivity analysis
A total of 461 participants had a linked incident hos-
pitalization record with a diagnosis of CDI in either
the principal (n = 187) or a secondary (n= 274) diag-
nosis ﬁeld. Compared to patients with CDI as a prin-
cipal diagnosis, patients with a secondary diagnosis of
CDI had higher comorbidity with 39·7% (183/461)
patients having a Charlson index of 51, and longer
hospital stays (median of 11 days compared to 6 days).
The rate of CDI hospitalization using this alternate
case deﬁnition was higher, at 39·9 (95% CI 36·5–43·8)/
100 000 person-years. The rates increased signiﬁcantly
with calendar year from 30·7/100 000 person-years
(95% CI 24·8–38·1) in 2009 to 72·0/100 000 person-
years (95% CI 58·6–88·4) in 2012. We observed a simi-
lar trend of incidence in hospitalization with CDI as a
principal diagnosis and hospitalization with CDI as
either a principal or secondary diagnosis (Fig. 2).
The quarterly incidence rates rose signiﬁcantly during
2011 to 2012, with a peak in October–December 2011.
The risk factor analysis yielded similar results to our
main analyses, except that use of PPIs was signiﬁ-
cantly associated with CDI hospitalization (aHR
1·3, 95% CI 1·1–1·5) (Supplementary Table S1).
DISCUSSION
In this large study of middle-aged and older adults, we
found a signiﬁcant increase in the incidence of CDI
hospitalization over 2009–2012, and an increase in
CDI hospitalization with increasing age. In industria-
lized countries, C. difﬁcile is one of the most frequent-
ly reported nosocomial pathogens. The elevated rates
in older adults, combined with the longer duration of
CDI-associated hospital stay and high hospital costs
in the elderly indicate a substantial burden and excess
hospital costs due to CDI in an ageing population.
Since mandatory reporting was introduced in
Australia, there has been a signiﬁcant increase in incidence
of hospital-identiﬁedCDI [6]. In our study, there is a simi-
lar trendof incidence between hospitalizationwithCDI as
a principal diagnosis and hospitalization with CDI as ei-
ther a principal or secondary diagnosis. Mandatory
reporting began in 2010while the rate increasedmarkedly
during 2011 and peaked by October–December 2011.
Compared to previous years, there is a signiﬁcant increase
Table 1. Characteristics of all participants and those
hospitalized with C. difﬁcile infection, 45 and Up Study
Variables
Population







45–54 77 874 (29·2) 22 (11·8)
55–64 85 855 (32·2) 32 (17·1)
65–74 58 060 (21·7) 49 (26·2)
75–84 36 873 (13·8) 63 (33·7)
585 8260 (3·1) 21 (11·2)
Sex
Female 143 101 (53·6) 120 (64·2)
Male 123 821 (46·4) 67 (35·8)
Region of residence
Cities 120 200 (45·0) 105 (56·2)
Inner regional 93 779 (35·1) 60 (32·1)
Outer regional 52 943 (19·8) 22 (11·7)
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in incidence of CDI hospitalization during 2011–2012,
which is unlikely to be due to changes in reporting but
could be due to changes in testing practices. Changes in
testing practices from enzyme immunoassay to nucleic
acid ampliﬁcation could result in improved detection of
cases [21]. In addition, an Australian study using whole
genome sequencing to describe the secular trends in the
prevalence of hospital-identiﬁedCDI found that the intro-
duction of newC. difﬁcile strains, alongside rises in the in-
cidence of established strains, may explain the observed
increase in CDI [22]. Although we were not able to iden-
tify the speciﬁc C. difﬁcile strains contributing to the hos-
pitalizations in this study, our results are in line with
published Australian data [6].
Fig. 1. Associations between baseline characteristics and incident CDI hospitalization, 45 and Up Study.
Fig. 2. Quarterly incidence of participants hospitalized with C. difﬁcile infection in the 45 and Up Study, 2009–2012.
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Notwithstanding the fact that CDI hospitalization
does not exclude patients that acquire CDI during the
hospitalization, nearly a third of CDI cases did not ap-
pear to be exposed to a hospital environment during
the 3 months prior to their hospitalization, suggesting
a community-acquired infection. Community-acquired
CDI is deﬁned as symptom onset in the community
over 12 weeks after the last discharge from a healthcare
facility (HCF), while HCF-acquired CDI is deﬁned as
symptom onset >48 h after admission to a HCF [23].
The recommendations for surveillance of C.
difﬁcile-associated disease are to report community-
onset HCF-associated CDI (deﬁned as a patient with
symptom onset in the community or 448 h after ad-
mission to an HCF) in addition to HCF-onset
HCF-associated CDI (deﬁned as a patient with symp-
tom onset >48 h after admission to an HCF) due to
the delayed onset of infection in the HCF [23]. In this
study, we found a relatively high proportion of cases
without inpatient hospital exposure in the previous 3
months. However, we were unable to assess whether
these cases had contact with the healthcare environ-
ment as outpatients, although the risk of acquiring
CDI in these settings has been considered low due to
limited contact time [24].
The rate of CDI hospitalization increased with age,
with the highest incidence observed in persons aged
585 years. This trend was in line with previous stud-
ies reporting that older people are at higher risk of ex-
periencing severe CDI than younger people [1, 8]. We
found that poorer self-rated health was also signiﬁ-
cantly associated with CDI hospitalization after ad-
justment for age, suggesting a signiﬁcant impact of
underlying health status. Comorbid illness and sever-
ity of underlying conditions have been reported as
risk factors for CDI, partially through their associ-
ation with greater healthcare contact [25, 26]. In add-
ition, people with poor general health may be more
likely to develop severe CDI, and therefore require
hospitalization.
In our study, females were at higher risk of CDI
hospitalization and the magnitude of relative risk
was more extreme than published data [8]. There are
contradictory reports concerning sex-speciﬁc differ-
ences in CDI [27, 28], although the overwhelming ma-
jority suggest a greater risk in females [29, 30]. The
reason for a higher risk in female observed in this
study is unknown. One hypothesis relates to females
being prescribed antibiotics more often than males
[31], and more likely to be associated with inappropri-
ate antibiotic prescribing [32]; therefore increasing risk
of CDI. Sex-speciﬁc differences in the gut microbiota
may also explain these ﬁndings [33]. Animal studies
have shown that androgen levels mediate gut microbiota
[34]. Sex differences in the diversity and abundance of
bacterial colonization in humans’ gastrointestinal tracts
may inﬂuence an individual’s susceptibility to infection
[35]. Further research is needed to conﬁrm the sex-
speciﬁc differences in CDI and to better understand
the mechanisms of this association.
We found that people living in remote or rural areas
had a lower risk of CDI hospitalization and the risk
decreased with increasing remoteness. This may be
associated with different health services models in cit-
ies, regional/outer regional and rural areas. People liv-
ing in remote areas may have less access to HCFs and
therefore, are less likely to experience HCF-acquired
CDI.
PPIs are associated with an increasing risk of CDI
[36], while other studies have not conﬁrmed this rela-
tionship [25]. In our main analysis, PPI use was not
associated with hospitalization with CDI as principal
diagnosis (aHR 1·1, 95% CI 0·7–1·5), but was a sign-
iﬁcant risk factor for CDI hospitalization when
expanding the case deﬁnition to combine principal
CDI diagnosis with secondary CDI diagnoses (aHR
1·3, 95% CI 1·1–1·5). While this difference in results
may in part reﬂect a lack of power in the main ana-
lysis, notably the combined CDI cases had longer hos-
pital stays and more severe comorbidity than patients
hospitalized with CDI as a principal diagnosis.
This is the ﬁrst prospective population-based cohort
study we are aware of to estimate the incidence of
hospital-identiﬁed CDI and examine potential risk
factors in Australia. The strengths of this study in-
clude a large sample size with linkage to hospitaliza-
tion and death records, and prospectively collected
data on a range of potential risk factors and confoun-
ders. The limitations include the relatively small num-
ber of cases which provide limited power to detect
signiﬁcant associations between certain risk factors
and CDI hospitalization. The use of inpatient hospi-
talization data may underestimate the burden of
CDI imposed on the community as cases not requiring
hospitalization were not included in the analysis.
Moreover, all the CDI cases were identiﬁed using
coded diagnoses. The accuracy of ICD-10 codes for
CDI has been assessed with 99·9% speciﬁcity and
35·6% sensitivity [37]. The trends in CDI rates for
ICD-10 codes identiﬁed cases and laboratory-
conﬁrmed cases strongly correlated, although con-
cordance was moderate. This may lead to an
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underestimate of the true population rates of CDI
compared with active surveillance [37]. Finally, the
45 and Up Study cohort tend to be healthier and
have a healthier lifestyle than the general NSW
population; therefore, our results may underestimate
the true incidence of CDI hospitalization in the gen-
eral population. However, risk factor estimates are
considered broadly generalizable from within-cohort
comparisons [38].
Despite concerted efforts in disease prevention, the
incidence of CDI hospitalization increased signiﬁ-
cantly between 2009 and 2012 in our study. Further
analysis of trends over time is needed to characterize
the possible seasonality of CDI in Australia. In add-
ition, studies are required to better understand the
mechanisms underlying the increased risk of CDI hos-
pitalization in women.
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Age group (years)     
45-54 2,400 28.0 6.0 6.6 
55-64 3,700 28.5 7.4 8.7 
65-74 6,100 25.4 8.6 19.9 
75-84 12,600 42.3 16.7 41.2 
≥85 21,800 36.6 26.4 69.4 











































































































































































































































Your answers and experiences are important to us. 
To help us read your answers, please write as clearly 
as possible using a BLACK or BLUE pen, and be sure 
to complete the questionnaire as shown: 
Please put a cross in the appropriate box(es) Yes No
OR put numbers in the appropriate box, e.g. 21st June 1945
age 2654916012
45 and Up Study Questionnaire 
for Women
day month year
1. What is your 
date of birth?
day month year
2. What is 
today’s date?
3. How tall are you 
without shoes? cm OR feet inches
(please give to the nearest cm or inch)
4. About how much 
do you weigh? kg OR stone lbs
5. What is the highest qualification you have completed?
(please put a cross in the most appropriate box) 
no school certificate or other qualifications
school or intermediate certificate (or equivalent) 
higher school or leaving certificate (or equivalent)
trade/apprenticeship (e.g. hairdresser, chef)
certificate/diploma (e.g. child care, technician)
university degree or higher
6. Are you of Aboriginal or Torres Strait Islander origin?
(you can cross more than one box)
No Yes, Aboriginal Yes, Torres Strait Islander
7. In which country were you born?
Australia please go to question 9
UK Ireland Italy China
Greece New Zealand Germany Lebanon
Philippines Netherlands Vietnam Malta
Poland other (please specify) _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
8. What year did you first come to live in 
Australia for one year or more? (e.g. 1970)
9. What is your ancestry? (please cross up to 2 boxes)
Australian English Irish Chinese
Italian Greek Scottish German
Lebanese Dutch Maltese Polish
Filipino Indian Croatian Vietnamese
other (please specify)  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
10. Do you speak a language other than English at home?
Yes No
11. Have you ever been a regular smoker?
Yes ▼ No If No – please go to question 12
How old were you when you started 
smoking regularly? years old
Are you a regular smoker now? Yes No
If No – how old were you when you 
stopped smoking regularly? years old
About how much do you/did you smoke on average each day?
(If you are an ex-smoker, how much did you smoke on average 
when you smoked?)
cigarettes per day pipes and cigars per day
12. About how many alcoholic drinks do you have each week?
one drink = a glass of wine, middy of beer or nip of spirits
(put “0” if you do not drink, or have less than one drink each week)
number of alcoholic drinks each week
13. On how many days each week 
do you usually drink alcohol? days each week
2 0
1 9
General questions about you
BLFF0710
The 45 and Up Study relies on the willingness of people in New South Wales to share information about 
their lives and experiences, to provide knowledge that will help people live healthy and fulfilling lives for
as long as possible. Participation is completely voluntary, and you are free to withdraw from the Study at 
any time. To take part, please read the participant information leaflet, then complete the questionnaire and
consent form and return them in the envelope provided. We very much hope you will be able to take part.
Any questions or comments? Please call the Study helpline: 1300 45 11 45 or go to www.45andUp.org.au
Auspiced by In collaboration with






14. What best describes your current situation? (please cross one box)
single married de facto/living with a partner
widowed divorced separated
15. What best describes your current housing? (please cross one box)
house flat, unit, apartment house on farm
hostel for the aged mobile home other
nursing home retirement village, self care unit
16. How many TIMES did you do each of these 
activities LAST WEEK?
(put "0" if you did not do this activity)
Walking continuously, for at least 10 minutes
(for recreation or exercise or to get to or from places)
Vigorous physical activity
(that made you breathe harder or puff and pant, like jogging,
cycling, aerobics, competitive tennis, but not household chores 
or gardening)
Moderate physical activity
(like gentle swimming, social tennis, vigorous gardening 
or work around the house)
17. If you add up all the time you spent doing each activity 
LAST WEEK, how much time did you spend ALTOGETHER 
doing each type of activity?
(put "0" if you did not do this activity)
hours minutes
Walking continuously, for at least 10 minutes
(for recreation or exercise or to get to :
or from places)
Vigorous physical activity
(that made you breathe harder or puff and pant, :
like jogging, cycling, aerobics, competitive tennis, 
but not household chores or gardening)
Moderate physical activity 
(like gentle swimming, social tennis, vigorous :
gardening or work around the house)
Questions about your family
18. Have your mother, father, brother(s) or sister(s) ever had:
(blood relatives only: please put a cross in the appropriate box(es))
heart disease breast cancer




Parkinson’s disease ovarian cancer
severe depression osteoporosis
severe arthritis hip fracture
do not know
19. How many children have you given 
birth to? children
(please include stillbirths but do not include miscarriages, 
please write “0” if you have not had any children)
How old were you when you gave birth 
to your FIRST child? years old
How old were you when you gave birth 
to your LAST child? years old
For how many months, in total, have 
you breastfed? months
(please add together all the time you spent breastfeeding 
all of your children; put “0” if you never breastfed)
Questions about your health
20. About how many hours a week are you exposed 
to someone else’s tobacco smoke?
hours per week hours per week
21. Have you ever used the pill or other hormonal contraceptives?
(e.g. the combined pill, mini pill, contraceptive implant or injections)
Yes ▼ No
If Yes, for how long altogether have you 
used hormonal contraceptives? years
(please write ‘0’ if you used them for less than a year in total)
If Yes, how old were you when you LAST 
used hormonal contraceptives? age
(please write your current age if you are still using them)
Which type of pill or other hormonal contraceptive 
did you use MOST RECENTLY?
“the pill”, combined pill (e.g. Microgynon, Levlen)
progesterone-only pill (“mini pill”) (e.g. Micronor, Noriday, Microval)
Depo Provera
contraceptive implant (e.g. Implanon, Norplant)
do not know
22. Have you ever used hormone replacement therapy (HRT)?
Yes ▼ No 
If Yes, for how long altogether have you 
used HRT? years
(please write ‘0’ if you used HRT for less than a year in total) 
Are you currently taking HRT? Yes No
If No, at what age did you stop? age
23. Have you taken any medications, vitamins or supplements 
for most of the last 4 weeks, including HRT and the pill?
Yes ▼ No
If Yes, was it: multivitamins + minerals multivitamins alone
fish oil glucosamine omega 3
paracetamol aspirin for the heart aspirin for other reasons
Lipitor Avapro, Karvea warfarin, Coumadin
Pravachol Coversyl, Coversyl Plus Lasix, frusemide
Zocor, Lipex Cardizem, Vasocordol Micardis
Nexium Norvasc Fosamax
Somac Tritace Caltrate
Losec, Acimax Noten, Tenormin Oroxine
omeprazole atenolol thyroxine
































please list any other regular medications or supplements here 
times in the 
last week
at home in other places(e.g. work, going out, cars)







24. Has a doctor EVER told you that you have:
(If YES, please cross the box and give your age when 
the condition was first found)
Yes





high blood pressure – when pregnant age
high blood pressure – when not pregnant age
stroke age
diabetes age







25. In the last month have you been treated for: 
(If YES, please cross the box and give your age 
when the treatment started)
Yes
cancer age
heart attack or angina age
other heart disease age
high blood pressure age
high blood cholesterol age








26. Are you NOW suffering from any other important illness?
Yes ▼ No 
27. Do you regularly need help with daily tasks because 
of long-term illness or disability? 
(e.g. personal care, getting around, preparing meals)
Yes No 
28. Does your health now LIMIT YOU 
in any of the following activities?
VIGOROUS activities
(e.g. running, strenuous sports)
MODERATE activities
(e.g. pushing a vacuum cleaner, playing golf)
lifting or carrying shopping
climbing several flights of stairs
climbing one flight of stairs
walking one kilometre
walking half a kilometre
walking 100 metres
bending, kneeling or stooping
bathing or dressing yourself
29. Have you ever had any of the following operations?
(If YES, please cross the box and give your 
age when you had the operation; give your 
age at the most recent operation if you 
have had more than one) Yes
removal of skin cancer age
hysterectomy age
both ovaries removed age
sterilisation (tubes tied) age




heart or coronary bypass surgery age
(include stents and balloons)
Please describe this illness and its treatment 
other (please describe any other operations you have had in the last 
10 years, with your age when you had them) 
type of cancer (please describe)























30. Do you regularly care for a sick or disabled 
family member or friend? 
Yes ▼ No 
If Yes, about how much time each week do you usually spend
caring for this person?
full time OR hours/wk




eyesight? (with glasses or 
contact lenses, if you wear them)
memory?
teeth and gums?
32. Do you feel you have a hearing loss? Yes No 
33. How many of your own teeth do you have left?
None – all of my teeth are missing 1-9 teeth left
10-19 teeth left 20 or more teeth left
34. During the past 12 months, how many times have you fallen 
to the floor or ground? (put “0” if you haven’t fallen in this time)
times
35. Have you had a broken/fractured bone in the last 5 years?
Yes ▼ No
If Yes, which bones were broken?
wrist arm hip ankle
rib finger/toe other_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
How old were you when it happened?
(give age at most recent fracture if more than one) years old
36. About how many times a week are you usually troubled 
by leaking urine?
never once a week or less
2-3 times 4-6 times every day
37. Have you been through menopause?
No 
Not sure (because hysterectomy, taking HRT, etc.)
My periods have become irregular
Yes – How old were you when you
went through menopause? years old
38. Have you ever been for a breast screening mammogram?
Yes ▼ No
If Yes, what year did you have your last 
mammogram? (e.g. 2005)
How many times have you been 
for breast screening altogether? times
39. Have you ever been screened for colorectal (bowel) cancer?
Yes ▼ No
If Yes, please indicate which test(s) you had:
faecal occult blood test (test for blood in the stool/faeces)
sigmoidoscopy (a tube is used to examine the lower bowel: 
this is usually done in a doctor’s office without pain relief)
colonoscopy (a long tube is used to examine the whole large bowel; 
you would usually have to have an enema or drink large amounts 
of special liquid to prepare the bowel for this)
What year did you have the most recent 
one of these tests? (e.g. 2005)
Questions about your diet
40. About how many times each week do you eat:
(please count all meals and snacks. put ‘0’ if never eaten 
or eaten less than once a week)
beef, lamb or pork
chicken, turkey or duck
processed meat
(include bacon, sausages, salami, devon, burgers, etc)
fish or seafood
cheese
41. About how many of the following do you usually eat:
slices or pieces of brown/wholemeal bread each week
(also include multigrain, rye bread, etc.)
bowls of breakfast cereal each week
If you eat breakfast cereal is it usually: (please cross)
bran cereal (allbran, branflakes, etc.) muesli
biscuit cereal (weetbix, other (cornflakes, 
shredded wheat, etc.) rice bubbles,etc.) 
oat cereal (porridge, etc.)
42. Which type of milk do you mostly have?
whole milk reduced fat milk skim milk
soy milk other milk I don’t drink milk
43. About how many serves of vegetables do you usually eat 
each day? A serve is half a cup of cooked vegetables or one cup of salad 
(please include potatoes and put “0” if less than one a day)
number of serves of cooked vegetables each day 
number of serves of raw vegetables each day (e.g. salad)
I don’t eat vegetables
44. About how many serves of fruit or glasses of fruit juice do you
usually have each day? A serve is 1 medium piece or 2 small pieces or
1 cup of diced or canned fruit pieces (put “0” if you eat less than one serve a day)
number of serves of fruit each day
number of glasses of fruit juice each day
I don’t eat fruit 
45. Please put a cross in the box if you NEVER eat: 
red meat chicken/poultry pork/ham dairy products
any meat eggs sugar wheat products
fish seafood cream cheese
Questions about time and work
46. What is your usual yearly HOUSEHOLD income before tax, 
from all sources? (please include benefits, pensions, superannuation, etc)
less than $5,000 per year $30,000-$39,999 per year
$5,000-$9,999 per year $40,000-$49,999 per year
$10,000-$19,999 per year $50,000-$69,999 per year
$20,000-$29,999 per year $70,000 or more per year

























Thank you very much for filling in the questionnaire 
DON’T FORGET TO SIGN THE CONSENT FORM OVERLEAF 
47. What is your current work status? (you can cross more than one box)
in full time paid work self-employed
in part time paid work doing unpaid work
completely retired/pensioner studying
partially retired looking after home/family
disabled/sick unemployed
other
48. If you are partially or completely retired, 
how old were you when you retired? years old
Why did you retire? (you can cross more than one box)
reached usual retirement age lifestyle reasons
to care for family member/friend ill health
made redundant could not find a job
other
49. About how many HOURS each WEEK do you usually spend
doing the following? (please put “0” if you do not spend any time doing it)
hours per week hours per week
paid work voluntary/unpaid work
50. Which of the following do you have? (excluding Medicare)
Private health insurance – with extras
Private health insurance – without extras
Department of Veterans’ Affairs white or gold card
Health care concession card
none of these
51. What best describes the colour of the skin on the inside of
your upper arm, that is your skin colour without any tanning?
very fair light olive brown
fair dark olive black
52. What would happen if your skin was repeatedly exposed 
to bright sunlight during summer without any protection?
Would it:
Get very tanned? Get mildly or occasionally tanned?
Get moderately tanned? Never tan, or only get freckled?
53. About how many hours a DAY would you usually spend
outdoors on a weekday and on the weekend?
hours per day hours per day
weekday weekend
54. About how many HOURS in each 24 hour DAY 
do you usually spend doing the following? 
(please put “0” if you do not spend any time doing it)
hours per day hours per day
55. How many TIMES in the LAST WEEK did you: 
(please put “0” if you did not spend any time doing it)
spend time with friends or family 
who do not live with you?
talk to someone (friends, relatives or others) 
on the telephone?
go to meetings of social clubs, religious groups 
or  other groups you belong to?
56. How many people outside your home, but 
within one hour of travel, do you feel you 
can depend on or feel very close to? people
57. During the past 4 weeks, 
about how often did you feel:
tired out for no good reason?
nervous?




so restless that you could 
not sit still?
depressed?
that everything was an effort?
so sad that nothing could 
cheer you up?
worthless?
58. During the past 4 weeks, have you had any of the following
problems with your work or daily activities because of any
emotional problems (such as being depressed or anxious)?
cut down on the amount of time you spent 
on work or other activities Yes No
achieved less than you would have liked to Yes No
did work or other activities less carefully 
than usual Yes No
Are your name and address correct on the front of this questionnaire? Yes No





State or Territory: Postcode:


















at night & naps) sitting
watching television
or using a computer standing







The 45 and Up Study relies on the willingness of people in New South Wales to share information about their lives 
and experiences and to have their health followed over time. By signing this form you are agreeing to take part in the 
45 and Up Study and for the Study team to follow your health over time. Participation is completely voluntary, and you 
are free to ask questions or to withdraw from the Study at any time, by calling the Study helpline on 1300 45 11 45.
More information on the Study can be found at www.45andup.org.au 
Consent form
I agree to have my health followed over time through:
the 45 and Up Study team following health and other
records relating to me, including NSW hospital records,
cancer records, death records and other health-related 
records, as outlined in the Study leaflet: The 45 and Up Study:
Information for participants;
Medicare Australia releasing to the 45 and Up Study my
enrolment details, including Medicare number, and information
concerning services provided to me under Medicare, the
Department of Veterans’ Affairs, the Pharmaceutical Benefits
Scheme and the Repatriation Pharmaceutical Benefits Scheme,
including past information, until the end of the Study or for 
the duration of my involvement in the Study;
being contacted in the future to provide information on
changes to my health and lifestyle. I may also be asked to
provide further information including questionnaire responses or
biological samples; my participation in any of these would 
be completely voluntary.
I give my consent on the understanding that:
my information will only be used for the purposes 
outlined in the Study leaflet entitled The 45 and Up Study:
Information for participants, of which I have a copy;
my information will be kept strictly confidential and 
will be used for health research only;
reports and publications from the Study will be based on 
de-identified information and will not identify any individual 
taking part;
my participation in this Study is entirely voluntary
and my consent will continue to be valid following death 
or disablement unless withdrawn by my next of kin or other
person responsible. I am free to withdraw from the Study at 
any time by calling the Study helpline on 1300 45 11 45;
my decision on whether or not to take part in the 
Study or in any additional research will not disadvantage 
me or affect my future health care in any way.
I have been provided with information about the 45 and Up Study including how it will gather, store, use and disclose information about
me, in the Study leaflet. I have been given an opportunity to ask questions and have been fully informed about the Study.
Name (Print):
day month year
Signature: Date today: 2 0
Extra contact details
It would be very helpful and reduce Study costs if we could contact you in future by email. If you are happy for us to do this, 
please write your email address here:
Email address:
Sometimes we find that people have moved when we try to contact them again. It would be very helpful if you could give us your mobile 
phone number and/or the contact details of someone close to you (such as a relative or friend) who would be happy for us to contact them 
if we are unable to reach you. We would only get in touch with that person if we were unable to contact you directly and we would need 









If you have any questions about the Study, please ring the Study helpline on 1300 45 11 45. 
You can also write to or send your questionnaire (no stamp required) directly to: 
Associate Professor Emily Banks, Scientific Director, 
The 45 and Up Study, Reply paid 5289, Sydney NSW 2001.
Thank you very much for taking part







Your answers and experiences are important to us. 
To help us read your answers, please write as clearly 
as possible using a BLACK or BLUE pen, and be sure 
to complete the questionnaire as shown: 
Please put a cross in the appropriate box(es) Yes No
OR put numbers in the appropriate box, e.g. 21st June 1945
age 2654916012
45 and Up Study Questionnaire 
for Men
day month year
1. What is your 
date of birth?
day month year
2. What is 
today’s date?
3. How tall are you 
without shoes? cm OR feet inches
(please give to the nearest cm or inch)
4. About how much 
do you weigh? kg OR stone lbs
5. What is the highest qualification you have completed?
(please put a cross in the most appropriate box) 
no school certificate or other qualifications
school or intermediate certificate (or equivalent) 
higher school or leaving certificate (or equivalent)
trade/apprenticeship (e.g. hairdresser, chef)
certificate/diploma (e.g. child care, technician)
university degree or higher
6. Are you of Aboriginal or Torres Strait Islander origin?
(you can cross more than one box)
No Yes, Aboriginal Yes, Torres Strait Islander
7. In which country were you born?
Australia please go to question 9
UK Ireland Italy China
Greece New Zealand Germany Lebanon
Philippines Netherlands Vietnam Malta
Poland other (please specify) _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
8. What year did you first come to live in 
Australia for one year or more? (e.g. 1970)
9. What is your ancestry? (please cross up to 2 boxes)
Australian English Irish Chinese
Italian Greek Scottish German
Lebanese Dutch Maltese Polish
Filipino Indian Croatian Vietnamese
other (please specify)  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
10. Do you speak a language other than English at home?
Yes No
11. Have you ever been a regular smoker?
Yes ▼ No If No – please go to question 12
How old were you when you started 
smoking regularly? years old
Are you a regular smoker now? Yes No
If No – how old were you when you 
stopped smoking regularly? years old
About how much do you/did you smoke on average each day?
(If you are an ex-smoker, how much did you smoke on average 
when you smoked?)
cigarettes per day pipes and cigars per day
12. About how many alcoholic drinks do you have each week?
one drink = a glass of wine, middy of beer or nip of spirits
(put “0” if you do not drink, or have less than one drink each week)
number of alcoholic drinks each week
13. On how many days each week 
do you usually drink alcohol? days each week
02
1 9
General questions about you
BLFM0710
The 45 and Up Study relies on the willingness of people in New South Wales to share information about 
their lives and experiences, to provide knowledge that will help people live healthy and fulfilling lives for
as long as possible. Participation is completely voluntary, and you are free to withdraw from the Study at 
any time. To take part, please read the participant information leaflet, then complete the questionnaire and 
consent form and return them in the envelope provided. We very much hope you will be able to take part.
Any questions or comments? Please call the Study helpline: 1300 45 11 45 or go to www.45andUp.org.au
Auspiced by In collaboration with






14. What best describes your current situation? (please cross one box)
single married de facto/living with a partner
widowed divorced separated
15. What best describes your current housing? (please cross one box)
house flat, unit, apartment house on farm
hostel for the aged mobile home other
nursing home retirement village, self care unit
16. How many TIMES did you do each of these 
activities LAST WEEK?
(put "0" if you did not do this activity)
Walking continuously, for at least 10 minutes
(for recreation or exercise or to get to or from places)
Vigorous physical activity
(that made you breathe harder or puff and pant, like jogging,
cycling, aerobics, competitive tennis, but not household chores 
or gardening)
Moderate physical activity
(like gentle swimming, social tennis, vigorous gardening 
or work around the house)
17. If you add up all the time you spent doing each activity 
LAST WEEK, how much time did you spend ALTOGETHER 
doing each type of activity?
(put "0" if you did not do this activity)
hours minutes
Walking continuously, for at least 10 minutes
(for recreation or exercise or to get to :
or from places)
Vigorous physical activity
(that made you breathe harder or puff and pant, :
like jogging, cycling, aerobics, competitive tennis, 
but not household chores or gardening)
Moderate physical activity 
(like gentle swimming, social tennis, vigorous :
gardening or work around the house)
Questions about your family
18. Have your mother, father, brother(s) or sister(s) ever had:
(blood relatives only: please put a cross in the appropriate box(es))
heart disease breast cancer




Parkinson’s disease ovarian cancer
severe depression osteoporosis
severe arthritis hip fracture
do not know
19. How many children have you fathered? children(please include stillbirths but do not include miscarriages, 
please write “0” if you have not had any children)
How old were you when you fathered your 
FIRST child? years old
How old were you when you fathered your 
LAST child? years old
20. Have you ever tried for more than 1 year but have been 
unable to father children?
Yes No
Questions about your health
21. About how many hours a week are you exposed 
to someone else’s tobacco smoke?
hours per week hours per week
22. Over the last month, 
how often have you:
found it difficult to postpone urination?
had to push or strain to start urination?
had a weak urinary stream?
stopped and started again several 
times when you urinated?
had to urinate again less than 2 hours 
after you finished urinating?
had the feeling that you had not emptied
your bladder completely after urinating?
Over the past month, how many times did you usually 
get up from bed to urinate during the night?
never some nights times each night
23. Have you taken any medications, vitamins or supplements 
for most of the last 4 weeks?
Yes ▼ No
If Yes, was it: multivitamins + minerals multivitamins alone
fish oil glucosamine omega 3
paracetamol aspirin for the heart aspirin for other reasons
Lipitor Avapro, Karvea warfarin, Coumadin
Pravachol Coversyl, Coversyl Plus Lasix, frusemide
Zocor, Lipex Cardizem, Vasocordol Micardis
Nexium Norvasc Fosamax
Somac Tritace Caltrate
Losec, Acimax Noten, Tenormin Oroxine
omeprazole atenolol thyroxine
































please list any other regular medications or supplements here 








at home in other places(e.g. work, going out, cars)






24. Has a doctor EVER told you that you have:
(If YES, please cross the box and give your age when 
the condition was first found)
Yes





high blood pressure age
stroke age
diabetes age








25. In the last month have you been treated for: 
(If YES, please cross the box and give your age 
when the treatment started)
Yes
cancer age
heart attack or angina age
other heart disease age
high blood pressure age
high blood cholesterol age








26. Are you NOW suffering from any other important illness?
Yes ▼ No 
27. Do you regularly need help with daily tasks because 
of long-term illness or disability? 
(e.g. personal care, getting around, preparing meals)
Yes No 
28. Does your health now LIMIT YOU 
in any of the following activities?
VIGOROUS activities
(e.g. running, strenuous sports)
MODERATE activities
(e.g. pushing a vacuum cleaner, playing golf)
lifting or carrying shopping
climbing several flights of stairs
climbing one flight of stairs
walking one kilometre
walking half a kilometre
walking 100 metres
bending, kneeling or stooping
bathing or dressing yourself
29. Have you ever had any of the following operations?
(If YES, please cross the box and give your 
age when you had the operation; give your 
age at the most recent operation if you 
have had more than one) Yes
removal of skin cancer age
vasectomy age
part of prostate removed age




heart or coronary bypass surgery age
(include stents and balloons)
Please describe this illness and its treatment 
other (please describe any other operations you have had in the last 
10 years, with your age when you had them) 
type of cancer (please describe)























30. Do you regularly care for a sick or disabled 
family member or friend?  
Yes ▼ No 
If Yes, about how much time each week do you usually spend
caring for this person?
full time OR hours/wk




eyesight? (with glasses or 
contact lenses, if you wear them)
memory?
teeth and gums?
32. Do you feel you have a hearing loss? Yes No 
33. How many of your own teeth do you have left?
None – all of my teeth are missing 1-9 teeth left
10-19 teeth left 20 or more teeth left
34. During the past 12 months, how many times have you fallen 
to the floor or ground? (put “0” if you haven’t fallen in this time)
times
35. Have you had a broken/fractured bone in the last 5 years?
Yes ▼ No
If Yes, which bones were broken?
wrist arm hip ankle
rib finger/toe other_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
How old were you when it happened?
(give age at most recent fracture if more than one) years old
36. About how many times a week are you usually troubled 
by leaking urine?
never once a week or less
2-3 times 4-6 times every day
37. How often are you able to get and keep an erection that 
is firm enough for satisfactory sexual activity?
always usually sometimes 
never I would rather not answer this question
38. Have you ever had a blood test ordered by your doctor 
to check for prostate disease? (PSA test)
Yes ▼ No
If Yes, what year did you have your last 
PSA test? (e.g. 2005)
How many times have you had a PSA 
test altogether? times
39. Have you ever been screened for colorectal (bowel) cancer?
Yes ▼ No
If Yes, please indicate which test(s) you had:
faecal occult blood test (test for blood in the stool/faeces)
sigmoidoscopy (a tube is used to examine the lower bowel: 
this is usually done in a doctor’s office without pain relief)
colonoscopy (a long tube is used to examine the whole large bowel; 
you would usually have to have an enema or drink large amounts 
of special liquid to prepare the bowel for this)
What year did you have the most recent 
one of these tests? (e.g. 2005)
Questions about your diet
40. About how many times each week do you eat:
(please count all meals and snacks. put ‘0’ if never eaten 
or eaten less than once a week)
beef, lamb or pork
chicken, turkey or duck
processed meat
(include bacon, sausages, salami, devon, burgers, etc)
fish or seafood
cheese
41. About how many of the following do you usually eat:
slices or pieces of brown/wholemeal bread each week
(also include multigrain, rye bread, etc.)
bowls of breakfast cereal each week
If you eat breakfast cereal is it usually: (please cross)
bran cereal (allbran, branflakes, etc.) muesli
biscuit cereal (weetbix, other (cornflakes, 
shredded wheat, etc.) rice bubbles,etc.) 
oat cereal (porridge, etc.)
42. Which type of milk do you mostly have?
whole milk reduced fat milk skim milk
soy milk other milk I don’t drink milk
43. About how many serves of vegetables do you usually eat 
each day? A serve is half a cup of cooked vegetables or one cup of salad 
(please include potatoes and put “0” if less than one a day)
number of serves of cooked vegetables each day 
number of serves of raw vegetables each day (e.g. salad)
I don’t eat vegetables
44. About how many serves of fruit or glasses of fruit juice do you
usually have each day? A serve is 1 medium piece or 2 small pieces or
1 cup of diced or canned fruit pieces (put “0” if you eat less than one serve a day)
number of serves of fruit each day
number of glasses of fruit juice each day
I don’t eat fruit 
45. Please put a cross in the box if you NEVER eat: 
red meat chicken/poultry pork/ham dairy products
any meat eggs sugar wheat products
fish seafood cream cheese
Questions about time and work
46. What is your usual yearly HOUSEHOLD income before tax, 
from all sources? (please include benefits, pensions, superannuation, etc)
less than $5,000 per year $30,000-$39,999 per year
$5,000-$9,999 per year $40,000-$49,999 per year
$10,000-$19,999 per year $50,000-$69,999 per year
$20,000-$29,999 per year $70,000 or more per year

























Thank you very much for filling in the questionnaire 
DON’T FORGET TO SIGN THE CONSENT FORM OVERLEAF 
47. What is your current work status? (you can cross more than one box)
in full time paid work self-employed
in part time paid work doing unpaid work
completely retired/pensioner studying
partially retired looking after home/family
disabled/sick unemployed
other
48. If you are partially or completely retired, 
how old were you when you retired? years old
Why did you retire? (you can cross more than one box)
reached usual retirement age lifestyle reasons
to care for family member/friend ill health
made redundant could not find a job
other
49. About how many HOURS each WEEK do you usually spend
doing the following? (please put “0” if you do not spend any time doing it)
hours per week hours per week
paid work voluntary/unpaid work
50. Which of the following do you have? (excluding Medicare)
Private health insurance – with extras
Private health insurance – without extras
Department of Veterans’ Affairs white or gold card
Health care concession card
none of these
51. What best describes the colour of the skin on the inside of
your upper arm, that is your skin colour without any tanning?
very fair light olive brown
fair dark olive black
52. What would happen if your skin was repeatedly exposed 
to bright sunlight during summer without any protection?
Would it:
Get very tanned? Get mildly or occasionally tanned?
Get moderately tanned? Never tan, or only get freckled?
53. About how many hours a DAY would you usually spend
outdoors on a weekday and on the weekend?
hours per day hours per day
weekday weekend
54. About how many HOURS in each 24 hour DAY 
do you usually spend doing the following? 
(please put “0” if you do not spend any time doing it)
hours per day hours per day
55. How many TIMES in the LAST WEEK did you: 
(please put “0” if you did not spend any time doing it)
spend time with friends or family 
who do not live with you?
talk to someone (friends, relatives or others) 
on the telephone?
go to meetings of social clubs, religious groups 
or  other groups you belong to?
56. How many people outside your home, but 
within one hour of travel, do you feel you 
can depend on or feel very close to? people
57. During the past 4 weeks, 
about how often did you feel:
tired out for no good reason?
nervous?




so restless that you could 
not sit still?
depressed?
that everything was an effort?
so sad that nothing could 
cheer you up?
worthless?
58. During the past 4 weeks, have you had any of the following
problems with your work or daily activities because of any
emotional problems (such as being depressed or anxious)?
cut down on the amount of time you spent 
on work or other activities Yes No
achieved less than you would have liked to Yes No
did work or other activities less carefully 
than usual Yes No
Are your name and address correct on the front of this questionnaire? Yes No





State or Territory: Postcode:


















at night & naps) sitting
watching television
or using a computer standing







The 45 and Up Study relies on the willingness of people in New South Wales to share information about their lives 
and experiences and to have their health followed over time. By signing this form you are agreeing to take part in the 
45 and Up Study and for the Study team to follow your health over time. Participation is completely voluntary, and you 
are free to ask questions or to withdraw from the Study at any time, by calling the Study helpline on 1300 45 11 45.
More information on the Study can be found at www.45andup.org.au 
Consent form
I agree to have my health followed over time through:
the 45 and Up Study team following health and other
records relating to me, including NSW hospital records,
cancer records, death records and other health-related 
records, as outlined in the Study leaflet: The 45 and Up Study:
Information for participants;
Medicare Australia releasing to the 45 and Up Study my
enrolment details, including Medicare number, and information
concerning services provided to me under Medicare, the
Department of Veterans’ Affairs, the Pharmaceutical Benefits
Scheme and the Repatriation Pharmaceutical Benefits Scheme,
including past information, until the end of the Study or for 
the duration of my involvement in the Study;
being contacted in the future to provide information on
changes to my health and lifestyle. I may also be asked to
provide further information including questionnaire responses or
biological samples; my participation in any of these would 
be completely voluntary.
I give my consent on the understanding that:
my information will only be used for the purposes 
outlined in the Study leaflet entitled The 45 and Up Study:
Information for participants, of which I have a copy;
my information will be kept strictly confidential and 
will be used for health research only;
reports and publications from the Study will be based on 
de-identified information and will not identify any individual 
taking part;
my participation in this Study is entirely voluntary
and my consent will continue to be valid following death 
or disablement unless withdrawn by my next of kin or other
person responsible. I am free to withdraw from the Study at 
any time by calling the Study helpline on 1300 45 11 45;
my decision on whether or not to take part in the 
Study or in any additional research will not disadvantage 
me or affect my future health care in any way.
I have been provided with information about the 45 and Up Study including how it will gather, store, use and disclose information about
me, in the Study leaflet. I have been given an opportunity to ask questions and have been fully informed about the Study.
Name (Print):
day month year
Signature: Date today: 2 0
Extra contact details
It would be very helpful and reduce Study costs if we could contact you in future by email. If you are happy for us to do this, 
please write your email address here:
Email address:
Sometimes we find that people have moved when we try to contact them again. It would be very helpful if you could give us your mobile 
phone number and/or the contact details of someone close to you (such as a relative or friend) who would be happy for us to contact them 
if we are unable to reach you. We would only get in touch with that person if we were unable to contact you directly and we would need 









If you have any questions about the Study, please ring the Study helpline on 1300 45 11 45. 
You can also write to or send your questionnaire (no stamp required) directly to: 
Associate Professor Emily Banks, Scientific Director, 
The 45 and Up Study, Reply paid 5289, Sydney NSW 2001.
Thank you very much for taking part
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